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1. INTRODUCTION 
Pertussis, or whooping cough, is a traditional childhood disease which has 
assumed to be vaccine-preventable. Pertussis can be a life-threatening disease, 
particularly for unimmunised newborns and partly immunised infants (1, 2). For 
adolescents and adults, pertussis might entail persistent or prolonged cough (3, 
4). Routine immunisation with killed pertussis vaccine started in the 1950s and 
was effective, reducing incidence by more than 90% (5). However, after almost 
70 years of vaccination, pertussis is the most common vaccine-preventable 
disease, even in countries with high immunisation coverages (6). Furthermore, 
during the last two or three decades, the resurgence of pertussis has been seen 
across most of the world (7). The reasons of the spread of pertussis are not 
entirely clear (8-10).  
In Estonia, trends in the incidence of pertussis have been similar to in other 
countries with high immunisation rates (11). After the low incidence in the 
1970s and 1980s, the reported incidence rates started to increase and were 
highest in 2010 at 97/100,000 (data from Health Board of Estonia), the highest 
in Europe (11).  
However, in Estonia, the real incidence of pertussis before our studies was 
unknown, mainly for three reasons: 
1) Only qualitative serology tests with mixed antigens were available until 
2012, and this test has low specificity; therefore, false positives may have 
occurred.  
2) Despite the high immunisation coverage of pertussis vaccines in infants, the 
highest incidence has been always reported among children.  
3) As adolescents and adults often have a mild or even asymptomatic course of 
the disease, their pertussis might be underdiagnosed and underreported. 
Pertussis is mandatory to report to the surveillance organisations in most 
countries, including Estonia (11), and therefore epidemiological studies based 
on reported data are easy to conduct. However, as pertussis might be mild or 
even asymptomatic, it is often unrecognised, undiagnosed, and thus unreported 
(12). Prospective studies in patients with persistent cough enable us to deter-
mine the prevalence of pertussis and clinical characteristics of the disease. 
However, only symptomatic cases are enrolled. To capture both symptomatic 
and asymptomatic cases, seroprevalence studies should be conducted (13). 
To date, four epidemiological studies about Estonia, all based on national 
surveillance data, have been published between 2000 and 2016 (6, 14-16). As 
stated previously, the main disadvantage of studies based on the nationally 
reported data is low sensitivity, as not all cases are diagnosed and reported. In 
addition, we suspected overdiagnosis of pertussis among children. Therefore, to 
determine the real prevalence of pertussis in Estonia, we conducted a pro-
spective study in patients with persistent cough and population-based seropre-
valence studies. 
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2. REVIEW OF THE LITERATURE 
2.1. Definition of pertussis 
Pertussis is a highly contagious disease of the human respiratory tract caused by 
the Gram-negative coccobacillus Bordetella pertussis, which belongs to the 
genus Bordetella in the family Alcaligenaceae (17). Less frequently, other 
species of genus Bordetella, such as B. parapertussis, B. bronchiseptica or B. 
holmesii have been identified as the cause of pertussis-like disease (18). 
B. pertussis is a strict human pathogen with no known animal or environ-
mental reservoir (19). B. pertussis is a fragile bacterium and is therefore very 
sensitive to external conditions, requiring special agar and conditions to grow in 
medium (20). B. pertussis is transmitted via aerosolised respiratory droplets and 
is highly contagious (21). In susceptible populations, the B. pertussis trans-
mission rate is close to 90% (22). The basic reproduction number (Ro) indicates 
the number of other people that one patient infects during the period of 
infectivity (23). In the case of pertussis, Ro is estimated to be about 10 in pre-
vaccine (24) and about 5.5 in highly immunised European countries (25). For 
example, in the cases of influenza and Ebola, Ro is evaluated to be about 1.5 and 
2.0, respectively (26, 27), but in the case of measles about 12 (28). 
 
 
2.2. First description of the disease and detection  
of the causative organism of pertussis 
The first description of pertussis was published after an epidemic in Paris in 
1578 by Guillaume de Baillou, who described it as a serious paroxysmal cough 
with posttussive emesis which mostly attacked children of four to ten months 
(29). In 1900, the causal agent of pertussis was described as ovoid bacillus in 
sputum of a 6-month-old infant with pertussis by Jules Bordet, but he was 
unable to isolate the microbe because of its instability (30, 31). Bordet and 
Octave Gengou first cultivated the pathogen at the Pasteur Institute in 1906 in a 
medium containing potato extract and blood, which is now known as Bordet 
Gengou agar (30, 32). In tribute to Bordet, this Gram-negative bacterium was 
called B. pertussis (30).  
 
 
2.3. Pathogenesis of pertussis 
Transmission of B. pertussis is only possible through inhalation of aerosol 
droplets containing the bacteria (21). Patients with either cough or asympto-
matic carriages might transmit B. pertussis to naive contacts (21, 33, 34). The 
bacteria adhere to ciliated airway epithelium in the upper portion of the respi-
ratory system to multiply and produce toxins. The toxins paralyse the cilia to 
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obstruct the clearing of the airways, damage epithelium, and cause local inflam-
mation of the respiratory tract and systemic effects (35, 36).  
B. pertussis has many virulence factors: some of them are important for 
adhesion and others for producing toxins (35, 36) (Table 1). 
 
 
Table 1: Main known virulence factors of B. pertussis 
 
Adhesins Toxins 
Fimbriae A-subunit of pertussis toxin 
B-subunit of pertussis toxin Adenylate cyclase toxin 
Filamentous hemagglutinin Tracheal cytotoxin 
Autotransporters* Lipopolysaccharide 
Polysaccharide capsule Dermonecrotic toxin 
Pertactin Autotransporters* 
 Polysaccharide capsule 
 “Cough toxin” 
* Vag8, BekA, BapC, SphB1, and TcFA 
 
 
The adhesins responsible for binding bacteria to host cells are B-subunit of 
pertussis toxin (PT), fimbriae (FIM), filamentous hemagglutinin (FHA), auto-
transporters (including pertactin [PRN]), and polysaccharide capsule (37). 
A-subunit of PT, adenylate cyclase toxin (ACT), lipopolysaccharide (LPS), 
tracheal cytotoxin (TCT), and autotransporters have roles in blocking the innate 
immune response, which allows the infection to progress (37, 38).  
The only unique virulence factor expressed by B. pertussis is PT, which is an 
A-B exotoxin. A-subunit possesses enzyme activity, and B-subunit binds PT to 
the host cell and allows the A-subunit to enter the cells (39). Once in the cell 
cytosol, A-subunit hydrolyses cellular NAD and transfers the released ADP-
ribose to G-proteins. This increases intracellular levels of cAMP, leading to 
interference with cellular functions and suppression of the phagocytic function 
of phagocytes. The systemic effects of the toxin regulated by cAMP include 
lymphocytosis, alteration of hormonal activities, and increased insulin and 
histamine production (37, 40, 41). 
In infants, the presence of hyperleukocytosis may be associated with fatal 
outcomes (42). The hyperleukocytosis is not caused by the increased leucocyte 
production; instead, there is an increase in the release of B and T lymphocytes 
into the blood from extravascular sites, and these cells recirculate rather than 
emigrate from the blood as they normally would (43, 44). Increased leukocyte 
mass in small pulmonary vessels can diminish blood flow by increasing pulmo-
nary vascular resistance, which may result in pulmonary hypertension, cardiac 
failure, and shock (45).  
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To date, it remains unclear how the bacterium is cleared from immune or 
nonimmune hosts and why the symptoms may last for many months even after 
the causative organism has been eliminated by host immune response or 
antibiotics (46). Pittman et al. (47) and Robbins et al. (48) have suggested that 
paroxysmal cough, the main manifestation of pertussis, is PT-mediated. How-
ever, infections caused by B. parapertussis, which does not express PT, also 
cause paroxysmal cough (49). The long duration of paroxysmal cough has also 
been associated with local tissue damage, but even in the case of the classical 
course of the disease, the paroxysms persist even longer than the expected reco-
very of the local tissue damage; therefore, Mattoo and Cherry have suggested 
that another, unidentified toxin might contribute to the continued paroxysmal 
cough (43).   
 
 
2.4. Clinical signs and symptoms of pertussis 
The incubation period is usually 7–10 days but may range from 7 to 21 days (50).  
The severity of clinical courses of pertussis may vary from asymptomatic 
carriage, typically in adolescents and adults, to a life threating disease in new-
borns and infants (18, 50, 51) (Figure 1). 
 
Figure 1. Overview of possible clinical presentation of pertussis 
Pertussis disease covers all symptomatic cases (both classical and mild pertussis). 
Asymptomatic cases have no symptoms, but B. pertussis colonises their nasopharynx, 
and transmission to naive subjects is possible. Pertussis infection comprises both 
symptomatic and asymptomatic cases.  
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The classical course of pertussis is mostly seen in unimmunised children and 
consists of three periods (52). During the catarrhal period, which lasts one to 
two weeks, pertussis is highly contagious, and the clinical characteristics are 
like those of typical upper respiratory tract infections: malaise, rhinorrhoea, 
sneezing, lacrimation, and mild cough with no or low-grade fever (18). During 
the catarrhal period, the severity of cough progresses (52). In the paroxysmal 
period, which usually lasts from three to six weeks, the classical symptoms of 
pertussis occur. During the paroxysms, the patient cannot breathe until the 
coughing has passed, and paroxysms might be followed by a sudden inspiration, 
the “whoop” (52). Frequency of paroxysms may vary from only once a day to 
as often as every 15 minutes (52). Sometimes after the paroxysms, posttussive 
emesis appears (52). The cough is particularly severe at night (38, 53). The 
patient generally feels fine and has no coughing episodes between paroxysms 
(52). The last period is called the convalescence stage, which may last for 
several months, during which the cough slowly improves (54). 
Adolescents and adults who have had previous contact with pertussis antigens 
usually have an atypical course of the disease (3, 13). Sometimes mild pertussis, 
characterised by nonparoxysmal cough for 1 to 2 weeks without classical pertus-
sis symptoms, is presented. Though the infection remains mostly asymptomatic in 
these age groups, B. pertussis colonises their nasopharynx, and they can transmit 
the pathogen to others (12, 55, 56). McGuiness et al. have published that among 
those over 50-years of age, the most common conditions diagnosed prior to 
pertussis were cough and bronchitis in cases of symptomatic pertussis (57).  
The other age groups with an atypical course of the disease are newborns and 
young infants, who may have no paroxysms or cough at all, but poor feeding, 
dyspnoea, cyanosis, bradycardia, and apnoea can occur (41, 58, 59). Infants are at 
the highest risk of serious disease and death due to pertussis (60, 61). 
 
 
2.5. Main complications 
Type and frequency of pertussis complications are associated with the age and 
immune status of the patient. The rate of complications is four times higher in 
infants under six months old than in others because this age group is un- or 
partly immunised (53).  
Major complications of pertussis are as follows (41, 54): 
 pulmonary (pneumonia, pulmonary hypertension, atelectasis, pneumothorax, 
pneumomediastinum, subcutaneous emphysema, and rib fracture) 
 neurologic (seizures, encephalopathy, and intracranial haemorrhage)  
 nutritional (emesis, dehydration, hypoglycaemia, and weight loss) 
 
Hospitalisation rates are highest among infants at 63% and 28% in those under 
6 months and those from 6 to 11 months, respectively (62). Among adolescents 
and adults, only 1–2% of patients are hospitalised, but in those at least 50 years 
of age, the hospitalisation rate is 6% (4). Between 1997 and 2000 in the USA, 
15 
20% of all reported pertussis cases were hospitalised, 5.2% had pneumonia, 
0.8% had seizures, 0.1% had encephalopathy, and 0.2% died (62). Bacterial and 
viral superinfections like influenza and respiratory syncytial virus (RSV) may 
also occur, which leads to a more severe clinical course (63, 64).  
The pertussis mortality rate is highest among infants (1). The risk factors 
associated with infant death from pertussis are low birth weight, young gesta-
tional age, young age at the time of cough onset, and high peak white blood cell 
and lymphocyte counts (65). Chow et al. (1) have systematically reviewed 
studies about pertussis mortality rates and concluded that overall pertussis 
mortality rate in the pre-vaccine era varied from 2 cases per million in Italy to 
1500 cases per million in Denmark (66, 67), pertussis mortality rate in infants in 
the pre-vaccine era varied from 307 per million in United Kingdom (UK) (68) 
to 6,200 per million in Senegal (69). The overall pertussis mortality rate ranged 
from 3.4–5.3 per million in the early vaccine era and decreased by 90% in later 
periods (1). Furthermore, the infant mortality rate decreased from 16.5 per 
million births in the early vaccine era to a later 7.2 in the UK and from 12.3 to 
2.4 in the USA (1, 64, 68, 70, 71). 
 
 
2.6. Laboratory testing of pertussis 
Direct methods such as nasopharyngeal culture and polymerase chain reaction 
(PCR) and the indirect method enzyme-linked-immunosorbent serologic assay 
(ELISA) are reliable and mostly used in diagnosing pertussis (22, 72). The sen-
sitivity, specificity, timing, advantages, and disadvantages of the different tests 
for diagnosing pertussis are presented in Table 2.  
The gold standard for the diagnosis of pertussis, culture, is highly specific 
but has poor sensitivity which decreases with the duration of the disease, treat-
ment of antibiotics, and increasing age of the patient (75, 80, 83). B. pertussis is 
very susceptible to environmental conditions, and therefore improper sampling 
and culture techniques may give false negative results. Because the immediate 
culture of specimen is usually unavailable in clinical practise, the transport 
medium of Regan-Lowe agar to prevent the loss of B. pertussis and inhibit the 
growth of other bacteria should be used (43). Bordet-Gengou and Regan-Lowe 
agars are the media most used to isolate B. pertussis (20), but the slow growth 
of bacteria may delay diagnosis up to 10 days (20, 84). 
Many assays to detect B. pertussis by PCR are available. However, none of 
them have been standardised across clinical laboratories until now (85). The 
most frequently used target genes of B. pertussis are insertion element (IS) 481 
and promotor of PT gene (ptxA–Pr) (72, 86). In clinical practise, PCR is more 
used than culture because of its higher sensitivity, faster diagnosis, and ability to 
detect inviable bacteria (84, 87). However, PCR is also not ideal because of its 
inability to distinguish between the colonisation and the disease (88), potential 
cross-reaction with other Bordetella species (19), and potential contamination 
during management (89).  
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In terms of serologic tests, many different ELISA tests are in use. Serum Re-
ference Standards are essential for comparison of both intra- and inter-labora-
tory estimates. Therefore, the World Health Organization (WHO) established 
the First International Standard for Pertussis Antiserum (coded 06/140) for the 
measurement of pertussis antibody concentrations in human serum in 2008 (90). 
The long-used qualitative ELISA tests with mixtures of antigens such as PT and 
FHA or with whole B. pertussis cells have low specificity and are not recom-
mended anymore (81, 91). Only PT antibodies are specific to B. pertussis; 
therefore, concentration of PT antibodies should be measured, and the result 
should be expressed in international units per millilitre (IU/ml) (20, 81, 91, 92). 
Previously, serological data has been published in many different units, but the 
numerical values of IU/ml are equivalent to the previously used ELISA units/ml 
(EU/ml) (81, 91), and the European Sero-Epidemiology Network (ESEN) 
units/ml (93) and 100 (Dutch) u/ml are equivalent to 125 IU/ml (94, 95). 
Serologic confirmation of pertussis can be performed using either paired sera 
or single-sample serology. Paired serology looks for on ≥ 100% increase or 
decrease in PT immunoglobulin G (IgG) concentration for at least two weeks 
(92). If there is no ≥ 100% change, but one of the samples shows antibody 
levels above the cutoff for single-sample serology (see below), the result can be 
interpreted as evidence of recent infection of B. pertussis (92). Single-sample 
serology is often used in clinical practise, but the cutoff values for PT IgG are 
not conclusive (20) and vary between 40 and 200 IU/mL (96-101). This might 
be influenced by the ELISA kit used, age group of study subjects, or immuni-
sation status and schedule of the country. The EU Pertstrain group have sug-
gested that a single sample cutoff of PT IgG with optimal sensitivity and speci-
ficity may be in the range of 60–75 IU/mL based on receiver operating charac-
teristic (ROC) curve analysis of data from Denmark, the Netherlands, and the 
UK (81). However, de Melker et al. suggested two cutoffs of PT IgG:  
125 IU/ml (sensitivity 81.0% and specificity 99.2%) and 62.5 IU/mL (sen-
sitivity 92.7% and specificity 96.4%) (96). The latter values have been used in a 
large seroepidemiological survey conducted in Western Europe, where the 
higher value indicates infection in the last 6 months and the lower value in the 
last 7–12 months (93). The lower cutoff of PT IgG is also suggested for out-
break situations (100). If diagnosis cannot be confirmed with single-sample 
serology but pertussis is suspected based on clinical symptoms, then PT IgG 
should be measured in a second (convalescent) serum sample two to four weeks 
later (92). If a second serum sample cannot be obtained, measurement of the 
concertation of PT immunoglobulin A (IgA) in addition to PT IgG is an 
alternative (92). The cutoff value of PT IgA is not broadly accepted, but in view 
of the relatively high specificity and low sensitivity, it may be between 10 and 
20 IU/mL (56, 81). In addition, in children under four years old, the IgA 
response to B. pertussis infection may be low or even absent (74, 102). A 
serologic diagnostic algorithm suggested by Riffelmann et al. (91) is presented 
in Figure 2. 
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Figure 2. Serologic diagnostic algorithm suggested by Riffelmann et al. (91) 
 
Currently, measurement of immunoglobulin M (IgM) against B. pertussis anti-
gen is not recommended because its reaction is very slow and often absent in 
immunised or previously infected populations (20, 103). However, Otsuka et al. 
have recently developed a novel IgM capture ELISA that measures serum anti-
Bordetalla pertussis Vag8 (autotransporter protein) IgM levels with higher 
diagnostic accuracy than commercial PT IgG ELISA tests; in addition, it was 
shown that anti-Vag8 IgM antibodies were induced earlier than PT IgG anti-
bodies in consecutive patients’ sera (104). However, this method is not avail-
able on the commercial market yet. 
Available serological tests cannot be used for one year after pertussis immu-
nisation to confirm the diagnosis, as these tests are unable to differentiate anti-
bodies from natural infection and vaccination (80, 81). However, Otsuka et al. 
have shown that paediatric diphtheria, tetanus, and acellular pertussis (DTaP) 
vaccines did not induce anti-Vag8 IgG antibodies in mice and therefore might 
be applicable as a diagnosis conformation method in recently immunised 
individuals (104).  
Litt et al. have found a correlation between the level of PT IgG in serum and 
PT IgG in oral fluid. Using cutoff points for PT IgG of 100 IU/mL for serum 
and 70 arbitrary units (AU) for the oral fluid, it was reported that 80% of 
seropositive subjects were also positive according to the oral fluid assay, and 
97% of seronegative subjects were also negative according to the oral fluid 
assay (82).  
He et al. conducted a study to describe the methods of laboratory confir-
mation for pertussis in the EU and European Economic Area/European Free 
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Trade Association (EEA/EFTA) countries (n=27) in 2010 and concluded that 
culture, PCR, and ELISA were available in 17, 18, and 20 countries, respec-
tively (72). All three methods were simultaneously available in only ten count-
ries (72). However, the distribution of confirmed cases according to laboratory 
methods was not studied. 
The distribution of laboratory-confirmed cases according to the laboratory 
methods in Denmark, England, Estonia, and the USA is presented in Figure 3. 
 
 
 
 
Figure 3. Distribution of laboratory confirmation methods used by country (105-
107) (data from Health Board of Estonia) 
In Estonia more than 90% of all pertussis cases are confirmed by serology. This result is 
similar to the data reported from England. In Denmark and the USA, direct methods 
like PCR and culture are mostly used to confirm pertussis diagnosis. 
 
2.7. Clinical case definitions of pertussis 
Many clinical case definitions of pertussis are used worldwide (108). The 
WHO (109), European Centre for Disease Control and Prevention (ECDC) 
(110) and US Centers for Disease Control and Prevention (CDC) (111) 
define clinical cases of pertussis similarly as any person with a cough lasting at 
least two weeks and combined with at least one of the following symptoms: 
paroxysms of coughing, inspiratory whooping, and posttussive vomiting (i.e. 
vomiting immediately after coughing) without other apparent cause (Table 3). 
In addition, the ECDC and CDC accept apnoeic episodes as a clinically defining 
symptom in infants (110, 111), while the WHO and ECDC accept a case 
diagnosed as pertussis by physician as a clinical case (109, 110). 
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2.7.1. Sensitivity and specificity of clinical case definitions 
Studies assessing the sensitivity and specificity of the WHO’s clinical case 
definition of pertussis have showed that these criteria perform poorly in dis-
tinguishing pertussis from other causes of cough lasting at least seven days. 
Although the sensitivity of the definition in studies conducted in the USA, Iran, 
and France was relatively high and varied between 79% and 100%, the 
specificity was low in all studies, ranging between 15% and 17% (112-114). In 
the French study, pertussis was defined as at least 21 days of paroxysmal cough 
according to the WHOʼs recommendations in 1991 (113, 115).  
We were not able to find any studies assessing the sensitivity and specificity 
of the ECDC clinical case definition. However, Gilberg et al. have estimated of 
the CDC’s 1990 case definition (a cough illness lasting at least two weeks with 
paroxysms of coughing, inspiratory “whoop”, or posttussive vomiting and with-
out other apparent cause (as reported by a health professional) and found high 
sensitivity (89%) and low specificity (11%) similar to those in the above-
described studies (113, 116).  
In 2011, Cherry et al. proposed more age-specific case definitions separately 
for the ages 0–3 months, 4 months–9 years, and 10 years and older. The key 
indicators of pertussis for younger infants are afebrile nature of the illness, 
cough that increases in frequency and severity, and a coryza that remains watery 
(108). The addition of apnoea, seizures, cyanosis, emesis, or pneumonia in-
creases both sensitivity and specificity (108). For children 4 months–9 years 
old, the presence of a worsening paroxysmal, non-productive cough of ≥ 7 days 
in an afebrile child with coryza that has not become purulent might also be sen-
sitive and specific to pertussis (108). The addition of classical pertussis symp-
toms like inspiratory whooping, posttussive emesis, and apnoea will increase 
specificity (108). For patients at least 10 years old, the triad listed for 4 months 
to 9 years would result in high sensitivity and good specificity (108). The 
presence of sweating episodes in older children and adults will significantly 
increase specificity (108). To the best of our knowledge, the prediction accuracy 
of these criteria has not been studied in any of these age groups until now.  
 
 
2.8. Laboratory criteria of pertussis 
The WHO, ECDC, and CDC have all defined their criteria for laboratory con-
firmation of pertussis (Table 3). All accept isolation of B. pertussis from a 
clinical specimen and/or detection of B. pertussis nucleic acid in a clinical 
specimen as confirmation (109-111). The differences between these three 
agencies are found in their use of serology for confirmation of diagnosis. The 
WHO recommends only positive paired serology, whereas the ECDC criteria 
require specific antibody response to B. pertussis and emphasise the necessity 
of interpretation according to immunisation status (109, 110). However, neither 
organisation defines accurate cutoff values. The CDC does not accept serology 
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as a laboratory confirmation method (111). However, US National Notifiable 
Diseases Surveillance System also collects the results of serology tests, and the 
percentage of reported pertussis cases with serology is increasing; therefore, the 
CDC analyses serologic assays currently available in the USA to help guide 
their routine use (107). 
The EU Pertstrain group has different recommendations for neonates and 
young infants than for older children and adults (Table 4) (81).  
 
 
Table 4. EU Pertstrain group recommendations for testing suspected pertussis (81) 
 
 Duration of cough Culture PCR PT-IgG* 
Neonates and young 
infants 
As soon as possible post-
onset of symptoms 
yes yes no 
Vaccinated children, 
adolescents, and adults 
< 2 weeks yes yes no 
Adolescents and adults 2–3 weeks no yes yes 
Adolescents and adults > 3 weeks no no yes 
* Serology cannot be interpreted if the last pertussis immunisation was less than 1 year 
ago. 
 
 
2.9. Pertussis vaccines and their effectiveness 
There are two types of pertussis vaccines available: whole-cell pertussis vaccine 
(wP), which contains the inactivated B. pertussis (~3,000 antigens), and acel-
lular pertussis vaccines (aP) consisting of detoxified PT and up to four other B. 
pertussis antigens (FHA, PRN, FIM 2, and FIM 3) (38, 117).  
Pertussis vaccines are routinely administered in combination with diphtheria 
and tetanus toxoid (DTwP or DTaP) (38). For adolescents and adults, dTap, 
with reduced concentration of diphtheria toxoid and pertussis antigens com-
pared to DTaP, has been introduced (118). 
The wP vaccine has been available since 1950s, and different manufactures 
have produced it using different strains of B. pertussis, technology to kill the 
bacteria by heating or with formalin, and adjuvants; therefore the available wP 
vaccines are relatively heterogeneous (38). The wP vaccines are not licenced for 
routine use in children, adolescents, or adults because of higher reactogenicity 
in these age groups (38). 
Since the 1980s, wP vaccines have been replaced with aP vaccines in many 
industrialised countries because of concerns about adverse reactions associated 
with them. The safety of wP vaccines has been reviewed, and there is no 
evidence that they cause brain damage or severe neurological disease (119, 
120). Alleged cases of wP vaccine encephalopathy appear to have been inborn 
genetic disorders (121, 122). Therefore, wP vaccines are still used, mainly in 
developing countries because of their lower cost (7, 30). 
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In developed countries, aP vaccines are widely used. Vaccines differ from 
each other in the number of antigen components, used bacterial clones, methods 
of purification and detoxification, and added adjuvants (38). Generally aP 
vaccines are less reactogenic than wP vaccines (123). The main reported side-
effects have been local redness and swelling and fever (58). The rate of these 
local side-effects after primary vaccination is very low, but the frequency and 
severity tend to increase with each subsequent dose of the aP vaccine (19, 58). 
However, among children who receive a booster dose of DTaP, the reported 
prevalence of local swelling is 2–6% (58). 
Measuring the effectiveness of pertussis vaccines depends on the case 
definition, age of vaccination, settings of exposure, time since vaccination, and 
vaccine characteristics, but similar efficacy levels have been suggested for both 
wP vaccines (46–92%) and aP vaccines (67–89%) (19, 38). In more recent 
studies, Fulton et al. estimated the effects of aP vaccines and wP vaccines on 
WHO-defined pertussis in children under 5 years old in meta-analysis and 
concluded that the effectiveness of wP was 94% (95% confidence interval [CI] 
88–97) and aP vaccine (three component and five component) 84% (95% CI: 
81–87) (124). As the herd immunity threshold for pertussis is estimated at 90–
94% (125), even a vaccine coverage rate of 100% would be insufficient to 
achieve complete elimination of pertussis (124). In the case of aP vaccines, one-
component and two-component vaccines have had lower efficacies than 
vaccines with ≥ 3 components (67–70% vs 80–84%) (38, 126, 127). Generally, 
in the first year after primary vaccination, the effectiveness against fatal and 
severe disease has been estimated at 100%, against typical disease at 90%, and 
against mild disease at 70%, and a single dose of vaccine is probably sufficient 
to prevent death from pertussis (19). In addition, in several studies, a milder 
course of the disease and shorter duration of cough in immunised patients with 
pertussis than in nonimmunised has been reported (128, 129).  
Initial data from the comparative clinical trials suggested that the duration of 
immunity from wP vaccines and aP vaccines is similar (130, 131), but epi-
demiological data suggested that immunity from aP vaccines wanes more 
rapidly, and a clear increase in reported incidence has been observed in adole-
scents who have been immunised only with aP vaccines (132-134). Wendelboe 
et al. have reviewed the published data on duration of immunity and concluded 
that the estimated durations of immunity after natural infection, after immu-
nisation with the wP vaccines, and after immunisation with the aP vaccines are 
7–20 years, 4–12 years, and approximately 6 years, respectively (135). McGirr 
et al. conducted a meta-analysis of the duration of pertussis immunity and 
estimated that every additional year after the last dose of DTaP, the odds of 
pertussis increased by 1.33 times (95% CI: 1.23–1.43), that 10% of children 
vaccinated with DTaP would be immune to pertussis 8.5 years after the last 
dose, and that there was no difference in the duration of immunity from 3- vs 5-
dose DTaP regimens (136). In addition, in adolescents immunised with dTap, 
the vaccine effectiveness during the first year after vaccination was 68.8% (95% 
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CI: 59.7–75.9), decreasing to 8.9% (95% CI: 30.6–36.4) by ≥ 4 years after 
immunisation (137).  
Although after immunisation the level of antibodies produced by antigens 
included in aP vaccines is higher than the level of the same antibodies after 
administration of wP vaccines, (138) the half-life of antibodies to pertussis 
antigens following natural infection after immunisation with aP vaccines and 
wP vaccines are similarly short at 6–12 months (139-141). It is known that the 
relationship between the level of antibodies and protection is not straight-
forward, and protective immunity against pertussis need both antibodies to a 
number of pertussis antigens and cell-mediated immune memory (132, 142). A 
recent study from Finland demonstrated that cell-mediated immunity persists 
even when antibodies have decayed (143). Data suggests that natural infection 
and wP vaccines induce T-helper cell 1 (Th1) responses, while the aP vaccine 
induces Th 2 or mixed Th2/Th1 responses (132, 144-147). After infection and 
vaccination with DTwP strong Th17 response in addition to Th1 memory has 
been reported in nonhuman primate models (33). Th17 and Th2 are specialised 
to control the extracellular bacterial and fungal infection at mucosal surfaces, 
and Th1 immune response provides protection from intracellular pathogens 
(132). As B. pertussis is an extracellular pathogen, then the role of Th1 is 
unclear (132). 
 
 
2.9.1. Immunisation schedule 
According to the WHO, there are more than 80 different pertussis immunisation 
schedules used worldwide (54). However, most of them consist of three doses 
in the first year of life followed by the first booster dose in the second year 
(148). In some countries, a second booster for children entering school and third 
for adolescents are added to the immunisation schedule (148).  
The WHO recommends a three-dose primary series to induce an immuno-
logical memory, with the first dose administered between 6 and 8 weeks of age; 
subsequent doses should be given 4–8 weeks apart (58). According to the 
ECDC, 22 countries start primary immunisation of pertussis at the age of 2 
months, and 9 countries start one month later (148). In addition, two types of 
schedules are used for immunisation under 24 months of age: the 2p+1 schedule 
(two doses of primary immunisation during the first 6 months of life and a 
booster dose at 11–12 months) and the 3p+1 schedule (three doses of primary 
immunisation during the first year of life and a booster dose in the second) 
(149). All EU/EEA countries have shifted to aP vaccines except Poland, which 
still uses wP vaccines for primary immunisation and the first booster dose 
(148). 
As unmeasurable or low antibody response will develop in some children 
after the primary doses and the immunity post-immunisation wanes, the booster 
doses are scheduled (150). The first booster dose is recommended at the age of 
1–6 years (at least 6 months after the last primary dose). In developed countries, 
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the first booster dose is usually administered at the age of 18–24 months, and 
the second booster dose to increase herd immunity at preschool age (148). In 
addition, some countries have already added a third booster dose to adolescents 
at the age of 14–16 years, as the prevalence of pertussis in this age group is 
highest in developed countries (93, 148).  
Adult boosters with dTap have also been recommended in some countries, 
but immunisation rates are generally low (148, 151).  
Recently, in many countries (the USA, the UK, Australia, Belgium, Ireland, 
Israel and some regions in Spain), maternal pertussis immunisation has been 
implemented to prevent pertussis in newborns (152-154). After immunisation of 
pregnant women, a high level of pertussis antibodies has been achieved, and 
some of them pass placenta and protect newborns during the first months of life, 
before the infant’s pertussis immunisation program starts (153). The WHO 
recommends immunising pregnant woman with dTap in the second or third 
trimester of pregnancy (at least 15 days before the expected delivery) (58). 
However, in a study conducted in the UK, blunt responses to some vaccines in 
the infant immunisation schedule after maternal immunisation were shown 
(155), but this should be monitored and according to Cherry, may be prevented 
by administering a booster dose in the second year of life (156). 
 
 
2.9.2. Pertussis immunisation in Estonia 
In Estonia, routine childhood immunisation using wP vaccines combined with 
diphtheria and tetanus toxoids was introduced in 1957 (Table 5) (14, 15). In 
2008, all doses of DTwP vaccines were replaced with DTaP (data from Health 
Board of Estonia).  
In general, the immunisation rate has been high (≥ 90%), except between 
1991 and 1998, when 76% of 1 year olds had the primary vaccination because 
of vaccine delivery problems (data from Health Board of Estonia) (15).  
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2.10. Global epidemiology of pertussis  
between 1940 and 2017 
Pertussis is an endemic disease with sporadic outbreaks and unique epidemic 
peaks every 3–5 years in both the pre-vaccine and vaccination eras (50, 58).  
Before vaccines became widely available in the 1950s, pertussis was one of 
the most common childhood diseases worldwide, affecting mostly children 
younger than five years, with the highest mortality rate occurring in children 
under one year of age (14, 50). In the USA, B. pertussis caused more than 
200,000 cases and up to 7,500 deaths yearly in the pre-vaccine era (5). The 
introduction of infant vaccination programmes was associated with a deep 
decline in the number of pertussis cases and deaths in children by the 1970s (58, 
62, 157). For example, the declines between the pre-vaccine and vaccine eras in 
cases and deaths of pertussis were 92.2% and 99.3%, respectively, in the USA 
(5). In Canada the reported pertussis incidence of 160/100,000 in the pre-
vaccine era was reduced to 11/100,000 by 1974–1983 (158). While B. pertussis 
caused about 73,000 deaths in the USA (mostly among infants) between 1922 
and 1931, the number of deaths decreased to 56 between 1983 and 1992 (159).  
The WHO has estimated that in 2008, about 16 million cases of pertussis 
occurred worldwide and 195,000 children died from the disease (160, 161). In 
2010, the number of reported cases worldwide was about 161,000 (162). The 
gap between estimated and reported numbers is huge, mainly because of under-
reporting due to unrecognition and underdiagnosing of pertussis (152).  
Domenech de Celles et al. reviewed the reported pertussis incidence data 
from 63 countries between 1980 and 2012 and showed that 32 countries had at 
least one period of increase in pertussis incidence (zero in Africa, eight in the 
Americas, four in the Eastern Mediterranean, eleven in Europe, five in southeast 
Asia, and four in the Western Pacific), but of those, 28 also had at least one 
period of decrease in pertussis incidence, whereas Australia, Israel, the Nether-
lands, and the USA experienced no decrease during the period studied (8). The 
switch to aP vaccines for primary vaccination has been associated with pertussis 
resurgence (33), but in Australia, the USA, Israel, the Netherlands, Finland, and 
Bulgaria, for example, the resurgence occurred prior to switching to aP vaccines 
(8, 163, 164). In addition, the decrease in reported pertussis incidence occurred 
after the switch to aP vaccines in different pertussis epidemic cycles: for 
example, in Finland after the period of high incidence, in Italy after the period 
of low incidence, and in Sweden after the period of no vaccination (8). Similar 
trends have been noted in countries where wP vaccines are used as a primary 
vaccination; the reported pertussis incidence increased alongside immunisation 
coverage in Brazil and Columbia, but decreased in Bolivia, Thailand, and 
Vietnam (8). However, the differences in the sensitivity of surveillance pro-
grammes might have influenced the analysis by Domenech de Celles et al. (8).  
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2.10.1. Pertussis surveillance and epidemiology in Europe 
In Europe, the ECDC routinely collects surveillance data on pertussis. In 2015, 
29 EU/EEA countries, excluding Liechtenstein and France, reported national 
data according to the ECDCʼs pertussis case definition (including clinical, epi-
demiological, and laboratory criteria) (154).  
The reported number of pertussis instances was about 40,000 in 2015, and 
incidence varies widely between countries (11). The highest incidence rate was 
in Norway, with 37/100,000, and no cases were reported from Malta or Luxem-
bourg (11). The mean notification rate between 2006 and 2015 in Europe has 
been 4–12/100,000 (11). During 2006–2015, a total of 101 pertussis-related 
deaths were registered in Europe (11). The distribution of the average notifi-
cation rate of pertussis by age group in Europe is presented in Figure 4. 
 
 
 
Figure 4. Distribution of the average notification rate of pertussis in different age 
groups in 2001–2005, 2006–2010, and 2011–2015 in Europe (11) 
 
2.10.2. Pertussis epidemiology in Estonia from 1945 to 2017 
The data on pertussis epidemiology has been collected by the Health Board of 
Estonia since 1945. The reporting system is based on mandatory reporting by 
physicians (passive surveillance). The epidemic curve of reported pertussis in 
the last 70 years is very similar to that in other developed countries (Figure 5) 
(16, 165). Prior to the adoption of national immunisation in 1957, the reported 
incidence rate had increased to 400/100,000. The immunisation programme was 
successful, and the reported incidence rate decreased to 2–4/100,000 in the 
1970s (15). The slight increase in the reported incidence rate started in the 
1980s, and the highest peak after the adoption of immunisation was achieved in 
2010 (incidence 97/100,000) (Figure 5) (165).  
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The distribution of the average notification rate of pertussis in different age 
groups in Estonia is presented in Figure 6. Mortality from pertussis has been 
very low in Estonia. The last reported death was in 2007 in a one-month-old 
child (6).  
 
 
 
Figure 6. Distribution of the average notification rate of pertussis among different 
age groups in 2001–2005, 2006–2010, and 2011–2015 in Estonia (11) 
 
 
2.11. Factors that may contribute to  
resurgence of pertussis 
Several factors have been observed to contribute to increase in pertussis, but the 
real role of each of them is still unknown: 
a) Waning natural and vaccine-induced immunities (76, 166): Immunity after 
both pertussis disease and immunisation (both wP and aP) wanes. It is esti-
mated that infection-acquired immunity lasts a maximum of 7–20 years, 
whereas protective immunity after immunisation with wP and aP wanes 
faster, after 4–12 years and approximately 6 years, respectively (135, 167, 
168).  
b) Lack of natural booster (76): Lavine et al. have suggested that because a 
primed immune system can respond to a lower dose of antigen than a naive 
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were frequently boosted by re-exposure, leading to individual long-lasting 
immunity. In the vaccine era, low pathogen circulation allows immunity to 
be lost before re-exposure occurs, which might explain the increased 
incidence among adolescents and adults (169).  
c) Use of less immunogenic vaccines (170): Cherry has proposed that efficacy 
of a vaccine increases directly with the number of antigens in it (171). 
Therefore, aP vaccines with higher quantities of B. pertussis antigens are 
preferable. However, wP vaccines contain ~3,000 B. pertussis proteins, 
many of which might contribute to protection (43). 
d) Improved diagnostic methods (166, 172): Development of more sensitive 
(though not as specific as culture) diagnostic methods such as PCR and sero-
logy, in addition to culture, afforded a better opportunity to diagnose pertus-
sis over a longer period of time and in adolescents and adults (9, 84, 173). 
e) Increased awareness: Cherry has pointed out that initial observations of 
increased pertussis in the 1980s and 1990s were due to a general increased 
awareness of pertussis because of the hundreds of publications at the time 
related to the development and study of acellular pertussis vaccines (174). In 
addition, increased awareness of pertussis in adolescents and adults was 
fostered by the use of single-sample serology (174).  
f) Changes in the genomic content of B. pertussis and differences between B. 
pertussis vaccine strains and circulating strains (166, 175-180): Data suggest 
that B. pertussis strains have changed over time and between the pre-vaccine 
and vaccine eras. Changes have been found in PT, FIM, and PRN. So far 
there is no evidence of a decrease in effectiveness of wP vaccines because of 
antigenic drift (181). However, in the case of aP vaccines, circulation of 
antigen-deficient isolates, especially non-expressed PRN, has been detected 
(182-185). 
g) Low vaccine coverage: A correlation between the decrease of vaccine 
coverage and increase of the disease has been reported in several studies (68, 
186). The WHO expects at least 90% of pertussis vaccine coverage in infants 
with three doses to ensure a high level of protection in children under five 
years of age (58). However, as the effectiveness of wP and efficacy of aP 
vaccines have been evaluated at 94% and 84%, respectively (124), and the 
herd immunity threshold for pertussis is estimated at 90–94% (125), even a 
vaccine coverage rate of 100% would be insufficient to achieve complete 
elimination of pertussis (124). 
h) Unvaccination or undervaccination (individuals who have received fewer 
doses of pertussis-containing vaccine than recommended according to their 
ages): Phadke et al. have reviewed 32 reports of pertussis outbreaks in the 
USA and concluded that unvaccinated and undervaccinated individuals have 
an increased risk of pertussis compared to fully vaccinated individuals (187). 
Glanz et al. have demonstrated that both unvaccinated and undrevaccinated 
children higher risk of laboratory-confirmed pertussis than fully vaccinated 
children (188-189).  
i) Real increase of pertussis. 
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2.12. Methods of studying pertussis epidemiology 
Pertussis epidemiology can be studied in the following three ways: (1) studies 
based on national surveillance systems, (2) prospective studies in patients with 
persistent cough, and (3) population-based seroprevalence studies (13). How-
ever, it is still difficult to compare the results of the same type of studies con-
ducted in different countries at different times. In addition to real differences, 
the results might be affected by differences in the stage of pertussis epidemic 
cycle (the highest rates occur during outbreak as compared to non-outbreak), 
age of population, vaccination coverage, type of vaccine used and immunisation 
schedules, and differences in laboratory methods used, and it is difficult to 
assess the impact of each factor (6, 190-192).  
Studies based on a national surveillance system analyse the cases collected 
by mandatory reporting and are divided into passive and active surveillance. 
Passive surveillance is the easiest method for getting the overview of the 
epidemiology of the disease, as its data relies on routine reporting. However, it 
has the main disadvantage of low sensitivity because of unrecognised and thus 
unreported pertussis cases (193). In active or enhanced surveillance, additional 
data of routinely reported cases is collected, and possible cases are actively 
pursued (166, 194, 195). Studies conducted by Plans et al. and Dominguez et al. 
have shown that under passive surveillance, a higher percentage of severe cases, 
cases in infants under one year of age, primary cases, hospitalisations, presence 
of apnoea, and laboratory-confirmed cases have been reported than under active 
surveillance (166, 194). If the household contacts of confirmed cases are not 
investigated, then 40% of cases will be missed, mainly in the adult population 
(166). The huge differences in pertussis prevalence in studies based on national 
reporting systems conducted in different countries and at different times 
(paragraph 2.12.1) may be explained by the sensitivity and specificity of the 
surveillance system and reporting only confirmed and/or confirmed and/or 
suspected cases, in addition to previously mentioned factors (6, 190-192). 
Prospective studies in patients with persistent or prolonged cough enable 
determination of the prevalence of pertussis. Because acute persistent or pro-
longed cough (of duration between three and eight weeks) is the most frequent 
symptomatic reason for visiting the general practitioner (GP), pertussis is not 
always investigated (196-200). During prospective studies, description of 
pertussis-specific symptoms, immunisation status, data of possible contact with 
coughing subjects, etc. can be studied in addition to prevalence. However, 
usually only symptomatic cases are enrolled, and a large number of asymp-
tomatic cases remain unknown. The overall high variability in prevalence of 
pertussis in patients with persistent cough (paragraph 2.12.2) may be partly ex-
plained by the recruitment criteria, methods of pertussis confirmation, and 
differences in doctor-seeking behaviour (201, 202). 
During population-based seroprevalence studies, levels of pertussis anti-
bodies are measured, and the estimated pertussis incidence can be calculated. 
Theoretically, this is an easy way to estimate the incidence rate of pertussis 
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infection, as it captures both pertussis disease and asymptomatic infection and 
enables comparison between times and countries (93, 152, 203-208). However, 
in addition to previously mentioned factors, the main difference between studies 
might be caused by the sensitivity and specificity of the ELISA tests used and 
differences in calculating estimated pertussis incidence (different cutoff values, 
use of simple percentage above the cutoff or of a specific formula such as de 
Melkerʼs [(203)]). In previous studies, levels of PT IgG of ≥ 125 IU/mL or 
 ≥ 100 IU/mL have indicated pertussis infection during the last 6 months, with  
≥ 62.5 IU/mL or 50 IU/mL suggesting pertussis infection in the previous year 
(93, 95, 96, 204). Various PT IgG levels, ranging from < 1 IU/mL (209) to 
 < 30 IU/mL (206), have been used to described negative sera in different 
studies, but most authors define sera with < 5.0 IU/mL as negative (81, 93, 96, 
204, 205, 207). However, sometimes this level may instead be the lower limit of 
detection of the test. Protective antibody levels are still not defined, probably 
because in addition to humoral immunity, the protection against pertussis is 
insure with cellular one (33, 96, 102, 152). 
 
 
2.12.1. Previous studies based on surveillance systems 
The overview of previously published epidemiological studies based on sur-
veillance data in different countries is presented in Table 6, and the reported 
incidence varies widely from 0.6 to 3,697.6/100,000. 
There is a great difference in incidence rates between studies based on 
passive and active surveillance, with higher incidence rates from the active ones 
during outbreaks (210-212) (Table 6). However, in two long-term studies based 
on passive surveillance conducted in Australia, similarly high yearly incidence 
rates have been reported (157, 213). The highest incidence is usually reported 
among infants (Table 6). 
One of the first comparative assessments of pertussis epidemiology, based 
on passive surveillance in 16 Western European countries in 1998–2002, was 
published by Celentano et al. in 2005 (Table 6) and observed high variability 
between countries. The highest incidence was reported in Northern and Central 
European countries: 124/100,000 in Switzerland, 57/100,000 in Norway, 
33/100,000 in the Netherlands, 22/100,000 in Sweden, and 10/100,000 in 
Germany. These five countries reported 89% of all cases. In all other countries, 
the incidence was less than 10/100,000 (214). Seven of 13 countries reported 
highest incidence among children under one year of age, while in Switzerland, 
it exceeded 1,000/100,000 and in five other countries 100/100,0000 (214). The 
incidence was highest in 1–4-year-olds in the Netherlands, in 5–9-year-olds in 
Sweden and in Malta, and in 10–14-year-olds in Norway and in Germany (214). 
The highest incidence in children other than infants might be explained by 
recent achievement of high immunisation coverage among infants and the lack 
of booster doses after primary immunisation (214, 215). However, the incidence 
among people older than 14 years doubled, and the median age of reported 
35 
cases increased from 7 years to 11 years between 1998 and 2002, which may be 
an effect of increased immunisation coverage and decreased frequency of 
natural boosters causing more cases in adolescence and adults (214).  
Recently, Heininger et al. undertook an epidemiological survey of annual 
incidences of pertussis based on national surveillance systems from 2000–2013 
in 10 Central and Eastern European countries and similarly highlighted large 
differences of reported pertussis incidence ranging from 0.01 in Hungary and 
Serbia to 96/100,000 in Estonia. In five countries, the highest burden was found 
among infants under one year old, but in others the highest incidence shifted to 
older children. This study identified the common problems with surveillance 
systems and a necessity to standardise pertussis detection and confirmation in 
surveillance programs across Europe (6). 
As presented in Table 6, the highest yearly incidence (3,698/100,000) is 
reported from an active surveillance study conducted during an outbreak in 
small town in Ireland in 2010 (210). Despite high immunisation coverage in this 
region, 70% of all cases were diagnosed among ≤ 18-year-olds, with the highest 
attack rates among < 3-year-olds (149/1,000) (210). 
A relatively long-term active surveillance study was conducted in Austria 
between 2000 and 2005, and the yearly incidence rate (9/100,000) was lower 
than in studies conducted during short outbreaks, as expected (216). However, 
the highest incidence was reported among < 1-year-olds (39/100,000) (216). 
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2.12.2. Previous clinical studies in patients with  
acute onset persistent cough 
The prevalence of pertussis among patients with persistent cough also varied 
greatly from 2.3% in Canada (201) to 37% in England (220) (Table 7).  
In 2016, Marchello et al. published a meta-analysis of prevalence of atypical 
pathogens in patients with cough and community-acquired pneumonia and re-
ported an overall prevalence of pertussis of 12.4% among mainly outpatients 
(95% CI: 4.9–19.8) (221). The prevalence was higher in studies conducted only 
in children (17.6%; 95% CI: 3.4–31.8) than in adults and children (8.9%; 95% 
CI: 6.7–11.2) (221). 
Recently, Teepe et al. conducted a prospective study in GP practices in 12 
European countries by enrolling 3,104 adults with cough lasting ≤ 28 days 
between 2007 and 2010, reporting a 3.0% prevalence of pertussis (95% CI: 2.5–
3.7). The prevalence varied from 0.0% in Italy to 6.2% in Sweden. Teepe et al. 
suggested that the differences among European countries might be caused by 
diversity in immunisation schedules and vaccines used, genetic variations of B. 
pertussis, and differences in doctor-seeking behaviour (202). 
A much higher prevalence of pertussis was reported in a prospective study 
conducted in England between 2001 and 2005 among immunised 5–16-year-old 
(at least one year previously) school children with cough lasting at least 14 
days; 64 of the 172 participants (37%; 95% CI: 30–44) had PT IgG more than 
100 IU/mL or an increase of at least four times in paired sample method (220). 
In another study based on an oral fluid PT IgG titre conducted in England 
among a similar age group approximately 10 years later, the prevalence was 
almost half that of the previous study (20%; 95% CI: 16–25) (222). Both studies 
were conducted in the moderate-low stage of the pertussis epidemic cycle and 
with immunisation coverage of at least 90%. This difference might be explained 
by the vaccines used, as England was switching from DTwP to DTaP during the 
first study, and the differences of the diagnosis confirmation methods. The high 
prevalence of pertussis in both English studies could be explained by the 
selected age group, as the national reported incidence of pertussis has almost 
always been lower in the UK than in other EU/EEA countries (11). However, 
another study on a moderate stage of a pertussis epidemic cycle using oral fluid 
serology with similar inclusion and laboratory criteria and approximately 10 
years after the DTaP was introduced, conducted in New Zealand, found a 
similar 17% prevalence of pertussis among school-age children (223). 
There were two studies conducted in countries still using DTwP. In a study 
conducted in Iran in 2007–2008 among children between ages 6 and 14 years 
with a cough lasting at least two weeks, the prevalence of pertussis based on 
culture and PCR was 6.4% (95% CI: 3.1–9.7) (114). In a study conducted in 
Brazil in 2010 and 2011, among subjects aged 10 years and older with a cough 
lasting between 14 and 30 days, the prevalence was a similar 5.2% (95% CI: 
2.0–8.4) based on culture, PCR, and epidemiological linkage (224). 
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2.12.2.1. Clinical characteristic of patients with pertussis and  
with cough of another or unknown aetiology 
Most of the studies conducted in patients with persistent cough assess only the 
prevalence of pertussis and do not compare the clinical characteristics in pa-
tients with pertussis and those with cough of another or unknown aetiology. If 
the symptoms are described and compared, then often no symptoms dis-
tinguishing patients with pertussis from those with a cough of another origin are 
reported (223, 226). 
However, in some studies the prevalence of paroxysms, posttussive emesis 
and inspiratory whooping are significantly higher in patients with confirmed 
pertussis than in others  (12, 112, 201, 220, 230, 232, 238) (Table 8). 
 
 
Table 8. Overview of studies which estimate the significant differences in pre-
valence of symptoms between patients with confirmed pertussis and with cough of 
another or unknown aetiology  
   Clinical characteristics (%)  
Loca-
tion 
Age 
group 
(years) 
Number of 
participants/ 
Number of 
confirmed 
cases 
Labo-
ratory 
methodsa 
Paro-
xysms 
Inspira-
tory 
whoop 
Post-
tussive 
emesis 
Other 
significant 
symptoms 
USA 
(112) 10–49 212/27 
Culture, 
PCR, 
serology 
- - + Posttussive gagging 
England 
(220) 5–16 172/64 Serology - + + 
Sputum 
production, 
wheezing 
Iran 
(114) 6–14 328/21 
Culture, 
PCR - - + N/A 
Spain 
(190)b All ages 963/555 
Culture, 
PCR + - + 
Cough ≥ 2 
weeks, 
apnoea, fever 
France 
(226) > 13 204/46 
PCR, 
serology - - - N/A 
Japan 
(230) 16–79 1,325/183 
PCR, 
serology + + - 
Posttussive 
gagging 
Korea 
(232) ≥ 11 490/34 
Culture, 
PCR - - + 
Sputum 
production, 
rhonchi 
Turkey 
(231) 10–39 214/15 
Culture, 
PCR + + + N/A 
a  At least one of the laboratory methods used should be positive to confirm pertussis. 
b Spain’s (190) laboratory-confirmed cases + cases epidemiologically linked to the laboratory-
confirmed cases 
+ presence of significant differences in prevalence of symptoms between patients with pertussis 
and with cough of another or unknown aetiology 
- – no significant differences in prevalence of symptom between patients with pertussis and with 
couch of another/unknown aetiology was reported 
N/A – not available 
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Harnden et al. found that among 5–16-year-olds, the prevalence of whooping 
(odds ratio [OR] 2.9; 95% CI: 1.4–5.8), vomiting (OR 4.4; 95% CI: 2.0–9.3), 
and sputum production (OR 2.4; 95% CI: 1.2–5.0) were significantly higher, but 
prevalence of wheezing (OR 0.5; 95% CI: 0.2–1.0) was significantly lower 
among patients with confirmed pertussis than in others (220). 
In a lengthy study conducted in Japan from 2005 to 2011, the prevalence of 
paroxysms, posttussive gagging, whooping, and exposure to cough by others at 
home, work, or school were significantly more associated with laboratory-
confirmed pertussis cases than with other causes of coughing (230). 
In 2017, two meta-analyses to determine the diagnostic accuracy of clinical 
characteristics of pertussis were published (239, 240). Ebell et al., based on 22 
studies with a total of 15,909 patients, concluded that overall clinical impression 
was the most accurate predictor of pertussis (positive likelihood ratio [LR+] 3.3; 
negative likelihood ratio [LR−] 0.63) (239). Although the overall clinical 
impression was quite specific (0.85), it lacked sensitivity (0.47); therefore, more 
than half of patients with pertussis might have been missed (239). The presence 
of whooping (LR+, 2.1) and posttussive vomiting (LR+, 1.7) increased the 
likelihood of pertussis, whereas the absence of paroxysms (LR−, 0.58) and 
sputum (LR−, 0.63) decreased it (239). Moore et al., based on 53 studies with a 
total of 23,790 patients, concluded that if an adult patient does not have paro-
xysmal cough or has a fever, they probably do not have pertussis, but the 
presence of posttussive vomiting or whooping raises suspicion of pertussis 
(240). In children, only posttussive vomiting was moderately sensitive (60.0%; 
95% CI: 40.3–77.0) and specific (66.0%; 95% CI: 52.5–77.3) (240). 
The duration of cough in patients with confirmed pertussis is usually signi-
ficantly longer than in patients with cough of another or unknown aetiology 
(Table 9). However, the overall duration of cough is a hindsight marker and does 
not aid in diagnosis. 
 
 
Table 9. Median duration of cough in days (range) in patients with confirmed 
pertussis and with cough of another or unknown aetiology 
Location Pertussis Cough of another or 
unknown aetiology 
p-value 
UK (220) 112 (38–191) 58 (24–192) N/A 
12 European countries (202) 17a (N/A) 12a (N/A) 0.008 
USA (112) 42 (27–66) 35 (4–77) 0.01 
Canada (201) 56 (N/A) 46 (N/A) 0.0006 
Iran (114) 30 (14–360) 20 (14–360) N/A 
N/A – not available 
a duration of cough after the index consultation 
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2.12.3. Previous seroprevalence studies 
The first large seroepidemiological study conducted by ESEN covered four 
countries with high (> 90%) immunisation coverage (Finland [DTwP], France 
[DTwP + DTaP], the Netherlands [DTwP] and East Germany [DTaP]) and three 
countries with moderate to low (< 90%) immunisation coverage (Italy [DTaP], 
West-Germany [DTaP] and the UK [DTwP]) and concluded that high con-
centration (> 125 IU/mL) sera were found across all countries and all age 
groups, but recent infection was more likely in adolescents (10–19 years old) 
and adults in countries with high immunisation coverage and more likely in 
children (3–9 years old) in countries with low immunisation coverage (93). 
Barkoff et al. have reviewed 44 seroprevalence studies from 23 countries  
all over the world and found that the seroprevalence of pertussis (PT IgG >  
62.5 IU/mL) ranged from 16 to 22,000 per 100,000 (152). These great diffe-
rences depended mostly on the age of the study groups, the sensitivity and 
specificity of the ELISA test used, the cutoff value, the timing of the study 
during the natural cycle of pertussis, immunisation coverage, vaccine type, 
immunisation schedule, and diagnostic methods available in clinical practice 
(152). However, all studies demonstrated a significant difference between 
nationally reported incidence and seroepidemiological data, and this indicates 
the spread of asymptomatic and/or mild disease, which causes the unrecognition 
and underreporting of pertussis (152). According to the seroepidemiological 
studies, it is difficult to conclude whether the change from wP vaccines to aP 
vaccines has affected B. pertussis circulation in the population, but booster 
doses of the aP vaccines have postponed the incidence peaks from children to 
adults (152). A similar shift has been not noted in countries still using wP 
vaccines (152). 
Both, the reported incidence and seroprevalence rate of pertussis were rela-
tively high in two Australian studies conducted in 1997–1998 (DTwP primary, 
DTaP boosters) and 2007 (DTaP), and the seroprevalence was about 300 times 
greater than the reported incidence rates (94, 204). A reduction in the per-
centage of population with antibody levels ≥ 62.5 IU/ml from 19% (95% CI: 
16–22) to 5% (95% CI: 4–6) in the ten years between the two studies was 
revealed (204). However, at the same time, the overall percentage of the 
population with PT IgG < 5 IU/mL increased significantly from 17% (95% CI: 
14–20) in 1997–1998 to 38% (95% CI: 36–40) in 2007 (204). The same trend 
occurred in all age groups. The collection of sera in 1997–1998 occurred during 
an epidemic period, which is consistent with the large percentage of population 
with high concentration of antibodies (204). After the 2007 study (with a high 
number of participants with PT IgG at undetectable levels), a large pertussis 
epidemic was reported in Australia (234). Despite high (89%) and moderate 
(55–76%) immunisation coverage with booster doses at ages of 4–5 years and 
15–17 years, respectively, the percentage of high level antibodies was about 
10% in both age groups in 2007 (241, 242). Campbell et al. concluded that 
vaccine-produced immunity wanes quickly in communities with low B. per-
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tussis circulation, in which natural boosting opportunities are reduced, and the 
low level of PT IgG antibodies may be an indicator of susceptibility at popu-
lation level (204).  
Sweden is the only European country where no universal pertussis immu-
nisation program existed between 1979 and 1996 (209). The prevalence of PT 
IgG was studied in two seroprevalence studies, the first performed one year 
after the resumption of the immunisation programme in 1997 (n=3,420) and the 
second 10 years later in 2007 (n=2,379) among subjects at least 2 years old 
(children vaccinated within the two years preceding the survey were excluded) 
(209). The proportion of sera with PT IgG < 1 IU/mL without vaccination was 
low (3.8%) in 1997 but had increased to 16.3% in 2007 (209). The proportion of 
sera with high PT IgG (> 100 IU/mL) was about 3% in both studies (209). In 
1997, the highest proportion of sera, with PT IgG > 100 IU/mL, occurred 
among 4–5-year-olds (approximately 11%), but 10 years later, it was only about 
1% (p=0.014), suggesting rapid decline of PT IgG antibodies after immuni-
sation (209). In two non-primary vaccinated age groups (14–15-year-olds and 
17–18-year-olds) the proportion of children with PT IgG > 100 IU/mL was 
higher in 2007 (~6%) than in 1997 (~4%) (p=0.11) (209). The difference was 
significant if a PT IgG cutoff of 50 IU/mL was used (p=0.046) (209). Among 
adults, the seroprevalences for a PT IgG cutoff of 50 IU/mL were 7–10% and 
4–8% in 1997 and 2007, respectively (p=0.052) (209). Hallander et al. con-
cluded that children’s pertussis vaccination has slowed down the transmission 
of pertussis, with a possible negative effect on population immunity (209). 
Seroprevalence studies are superior to epidemiological studies based on 
reported data and studies conducted in coughing patients because they are able 
to determine all pertussis cases (from asymptomatic to classical ones). In 
Europe, the gap between the rate of seroprevalence and reported incidence 
varies from about 80 times in The Netherlands in 1995–1996 to about 9,000 
times in Italy in 2004–2005 (Table 10). As shown in Figure 7, no correlation 
was found between reported incidence and seroprevalence based on the data 
from Table 10. 
. 
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Figure 7. Correlation between reported incidence and seroprevalence per 100,000 
people 
Each point indicates the results of reported incidence and seroprevalence of a study 
from Table 10. Cutoff values of at least 100 IU/mL were used. The line indicates the 
trendline. No correlation between reported incidence and seroprevalence among diffe-
rent studies was found. 
 
 
The main problem of seroprevalence studies is recent immunisation, as both 
immunisation and contact with B. pertussis increase antibody levels (81, 93, 
203, 253). Therefore, it is not possible to estimate pertussis seroprevalence by 
the increase in PT IgG antibodies in recently immunised populations, but in 
these age groups, the level of these antibodies could be compared after immu-
nisation with different vaccines in cases of different immunisation schedules. 
In studies conducted in the Netherlands in 1995–1996 (the DTwP era) and 
2006–2007 (the DTaP era), the levels of PT IgG in recently immunised children 
were studied (245). While in the first study, only 0.9% (95% CI: 0–2) of one-
year-olds had PT IgG ≥ 62.5 IU/mL, in the second study already 32% (95% CI: 
21–43) had PT IgG ≥ 62.5 IU/mL (245). However, a sharp decrease occurred, 
and only 2% had PT IgG ≥ 62.5 IU/mL a year later. The next peak of a high 
percentage of participants with PT IgG ≥ 62.5 IU/mL was revealed at the age of 
booster dose, but the following peak started only four years later and might 
have been associated with waning immunity and new natural infection (245). 
Pebody et al. have also studied the proportion of PT IgG > 125 IU/mL in 
infants primary-vaccinated with DTwP or DTaP and found prevalences of 0–
4.3% and 4–13.3%, respectively (93). 
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2.13. Summary of literature 
Despite high childhood pertussis immunisation rates, reported incidence has 
been increasing in many countries recently, including Estonia (10). As pertussis 
is mandatory to report to national surveillance organisations in most countries, 
most epidemiological studies have been based on passive surveillance because 
they are easiest to perform. However, such studies have low sensitivity due to 
unrecognised and underreported cases (193). Another way to characterise 
pertussis epidemiology is to conduct seroepidemiological studies, which capture 
both symptomatic and asymptomatic cases. To date, no studies of this type have 
been conducted in Estonia. Even those conducted in the other countries have not 
captured entire lifespan, having instead been focused on specific populations, 
usually children.  
Cough is a common reason to seek medical care; however, the cause of 
cough often remains unknown (199). In the pre-vaccine era, pertussis was 
mostly a childhood disease and mostly diagnosed based on classical pertussis 
symptoms such as paroxysmal cough, posttussive emesis, and inspiratory 
whoop (109). In the vaccine era, the sensitivity and specificity of the clinical 
characteristics and course of pertussis are unknown.  
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3. AIMS OF THIS RESEARCH 
The general aim of this thesis is to describe the epidemiology and clinical cha-
racteristics of B. pertussis infection in Estonia in a population with a high rate 
of childhood pertussis immunisation and to evaluate whether the current immu-
nisation schedule is sufficient in preventing pertussis. 
 
The study had the following objectives: 
1. To determine the concentration of the PT IgG type antibodies in the Estonian 
population across an entire lifespan; 
2. To estimate the incidence of B. pertussis infection among adults and children 
not recently immunised;  
3. To compare estimated incidence of pertussis based on PT IgG with the 
officially reported national figures on pertussis disease; 
4. To define the prevalence of pertussis and parapertussis in patients who have 
sought medical care for a cough of unknown aetiology that had lasted for ≥ 7 
days; 
5. To determine and compare the clinical characteristics of pertussis to those of 
parapertussis and cough of another or unknown aetiology and to determine 
how well the WHO’s clinical case definition of pertussis predicts the 
disease; 
6. To determine the course of pertussis and parapertussis. 
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4. MATERIALS AND METHODS 
This thesis is based on the results of three studies as detailed in Table 11. 
 
 
Table 11. Description of studies of the thesis 
Study 
name 
Study populations Timing Primary aims Pub-
lica-
tion 
Study 1:  
A sero- 
prevalence 
study in 
children 
Subjects 0–17 years 
old (n=1,053) with 
available laboratory 
leftover sera 
09.04.2012–
23.08.2012  
To estimate the incidence of B. 
pertussis infection among 9–
14-year-olds; 
To compare the estimated and 
reported incidence of pertussis. 
I 
Study 2:  
A seropre-
valence 
study in 
adults 
Subjects 18–99 
years old (n=3,425) 
with available 
laboratory leftover 
sera 
07.01.2013–
27.02.2013  
To estimate the incidence of B. 
pertussis infection; 
To compare the estimated and 
reported incidence of pertussis. 
II 
Study 3:  
A study in 
coughing 
patients 
Outpatient and 
hospitalised patients 
with persistent 
cough of all ages 
(n=549) 
23.04.2012–
31.12.2014 
To determine the prevalence of 
pertussis and parapertussis; 
To compare the symptoms of 
pertussis, parapertussis, and 
coughs of another or unknown 
aetiology. 
III 
 
 
4.1. Design and population of the studies 
A seroprevalence study in children consisted of cross-sectional serosurveys 
and included consecutive laboratory leftover sera of hospitalised and outpatient 
subjects younger than 18 years old with any diagnosis. Sera was collected at the 
Children’s Clinic of Tartu University Hospital, one of the two paediatric 
hospitals in Estonia. Sera from patients with suspected or confirmed pertussis 
were excluded. The only information available was the subject’s age.  
A seroprevalence study in adults also consisted of cross-sectional sero-
surveys and included consecutive laboratory leftover sera of outpatient subjects 
aged 18–99 years with any diagnosis. Sera was collected at Synlab Eesti OÜ 
laboratories (the largest private medical laboratory in Estonia). Sera from 
patients with suspected or confirmed pertussis were excluded. The only infor-
mation available was the subject’s age and gender. 
A study of coughing patients was a prospective observational study 
conducted among 25 GP practices, two referral hospitals (Tartu University 
Hospital and Tallinn Childrenʼs Hospital), and one district hospital (Järvamaa 
51 
District Hospital). It included patients of all ages with cough of unknown 
aetiology that had lasted for ≥ 7 days with no signs of recovery. We used time-
dependent inclusion criteria to identify cough lasting ≥ 7 days instead of the  
≥ 14 days recommended by the WHO, ECDC, and CDC to also detect clinically 
mild, culture, and PCR-positive cases. 
 
 
4.2. Study procedures 
In seroprevalence studies, 200 µl to 2 mL of randomly selected leftover labo-
ratory sera were collected to the studies according to the subjectsʼ age. In a 
seroprevalence study in children, samples were first stored at +2 to +8◦C for a 
maximum period of one week and then at −80◦C for a maximum period of eight 
months until analysed. In a seroprevalence study in adults, all sera were stored 
at +2 to +8◦C and analysed within 48 hours of collection. Persons between 20 
and 99 years old with PT IgG ≥ 62.5 IU/mL were identified. These subjects’ 
GPs were contacted and asked whether their patient(s) had complained of 
coughing during the six months preceding serum sampling. 
Data collection and monitoring in a study of coughing patients. During 
patients’ first visits, demographic data, onset time, and presence of basic 
symptoms (paroxysm, inspiratory whooping, posttussive emesis, apnoea, and 
fever) and additional symptoms (other complaints patients submitted to doctors, 
e.g. sleeping disturbances, rhinitis, sore throat, sweating, etc.), severity of cough 
on a Likert scale from 0–10 (0 = no cough; 5 = discomfort, cough interferes 
with sleeping; 10 = cough is unbearable, very painful, with constant fear of suf-
focation) and number of paroxysms according to the patients and/or their 
parents or guardians were collected in an electronic case report form created 
specifically for this project. Details of patients’ pertussis immunisations based 
on their immunisation passports, GPʼs database, or self-reporting were also 
collected in an electronic case report form. Only patients with confirmed 
pertussis and parapertussis were further monitored by recording presence of 
symptoms via weekly telephone or e-mail contact until they had recovered or 12 
weeks had passed, whichever occurred first. The presence of cough was 
monitored until complete recovery. 
Sample collection and storage in a study of coughing patients. Two 
nasopharyngeal swabs (NPS) and one sample of whole blood were collected. 
One NPS was placed into a Regan-Lowe transport medium (Copan Italia®, 
Brescia, Italy) and stored on site at +4˚C for a maximum of 24 hours before 
being transported to the laboratory. The second NPS was placed into a sterile 
tube and stored at room temperature for a maximum of 12 hours or at +4˚C for a 
maximum of five days before being analysed in the laboratory. Approximately 
1 ml of whole blood was collected in a tube with a clot activator and stored at 
+4˚C for a maximum of five days.  
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4.3. Laboratory testing 
The swabs of Regan-Lowe transport medium were analysed in Health Board of 
Estonia or Tartu University Hospital laboratories. After defreezing, the swabs 
were placed directly into charcoal agar (OXOID CM0119®, Basingstoke, UK) 
and incubated at 35°C and 60–70% humidity for 10 days. Plates were visually 
inspected daily and microorganisms identified using Matrix Assisted Laser 
Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS; 
Bruker Daltonics, Bremen, Germany). 
Swabs of sterile tubes were analysed using an in-house PCR test at Synlab 
Eesti OÜ or a commercial PCR kit (Diagenode Bordetella [pertussis/para-
pertussis] Real-Time PCR kit; Liège, Belgium) at Tartu University Hospitalʼs 
laboratory. For the in-house PCR test, two primers derived from unique de-
oxyribonucleic acid (DNA) sequences, upstream of the porin genes of B. per-
tussis (5'-ATGCTTATGGGTGTTCATC CGGCC-3') and B. parapertussis/  
B. bronchiseptica (5'-CGTCCAC CAGGGGTGGTAGGAGAT-3'), and a third 
primer (5'-TGCAACATCCTGTCCCCTTAATCC-3') shared by both species 
were used (254).  
Antibodies against PT were analysed at the Tartu University Hospital or 
Synlab Eesti OÜ laboratories using a commercial ELISA kit (Euroimmun®, 
Lübeck, Germany) according to the manufacturer’s protocol. Concentration of 
the PT IgG was measured in all studies. In addition, PT IgA was measured in a 
study of coughing patients if PT IgG was 40–100 IU/mL. The sensitivity and 
specificity of the PT IgG assay were 100% and 95.5%, respectively, and of the 
PT IgA assay 100% in both categories.  
 
 
4.4. Definitions 
Adults – people aged ≥ 18 years 
Children – people aged 0–17 years 
Cough of another or unknown aetiology – a persistent cough without 
pertussis or parapertussis confirmation by culture, PCR, and/or serology  
High concentration of PT IgG antibodies – PT IgG 62.5 to < 125 IU/mL, 
suggesting pertussis infection or immunisation in the preceding 7–12 months 
(93, 95, 96, 204) 
Infants – people aged 0–12 months 
Mid-range concentration of PT IgG antibodies – PT IgG 5 to < 62.5 IU/mL, 
suggesting pertussis infection or immunisation more than 12 months pre-
viously (93, 95, 96, 204) 
Parapertussis – B. parapertussis isolated by culture and/or positive PCR 
People not recently immunised – cohorts not immunised with pertussis 
vaccine during the previous year 
Persistent or prolonged cough – cough of duration between three and eight 
weeks (196, 197) 
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Pertussis – B. pertussis isolated by bacterial culture and/or positive PCR and/or a 
single PT IgG > 100 IU/ml or PT IgG 40–100 IU/ml and PT IgA > 12 IU/ml 
in the absence of immunisation for pertussis within the previous 12 months 
(91) 
Undetectable concentration of PT IgG antibodies – < 5 IU/mL (93, 95, 96, 
204) 
Very high concentration of PT IgG antibodies – PT IgG ≥ 125 IU/mL, 
suggesting pertussis infection or immunisation in the last 6 months (93, 95, 
96, 204) 
 
4.5. Statistics and data analysis 
Data on the annual notified incidence of pertussis and immunisation  
coverage were derived from reports of the Health Board of Estonia 
(http://www.terviseamet.ee/nakkushaigused/nakkushaigustesse-haigestumine.html 
and http://www.terviseamet.ee/nakkushaigused/vaktsineerimine/riiklik-
immuniseerimiskava-ja-selle-taitmine.html). The size of the general population 
was obtained from the databases of Statistics Estonia (http://pub.stat.ee/px-
web.2001/Database/Rahvastik/01Rahvastikunaitajad_ja_koosseis/04Rahvaarv_ 
ja_rahvastiku_koosseis/04Rahvaarv_ja_rahvastiku_koosseis.asp). 
All statistical analysis was performed using Microsoft Excel 2013 and 
Stata 12.1 for seroprevalence studies and R 3.1.1 (www.r-project.org), SAS 9.4 
(SAS Institute Inc., Cary, NC, USA), MS Excel 2013, and Medcalc® 
(https://www.medcalc.org/index.php) for study of coughing patients.  
 
 
4.5.1. Sample size calculations 
For the seroprevalence studies, the required sample sizes were calculated based 
on the estimated incidence of pertussis infection of 7–9% in the Netherlands 
(203, 245). Accordingly, 55 ± 6 subjects were required in each yearly cohort for 
ages 0–19 and at least 369 subjects for each eight 10-year age cohort (20–29, 
30–39, … 90–99) for other ages. 
According to previously conducted studies, the prevalence of pertussis 
among patients with persistent cough varies widely (Table 7). We hypothesised 
that the estimated prevalence of pertussis in patients with persistent cough is 
about 10% in Estonia. Accordingly, 900 patients, or at least 100 laboratory-
confirmed pertussis cases, would allow for an estimation of the prevalence of 
pertussis with a 95% CI: ±2%.  
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4.5.2. Analysis of PT IgG concentration in the entire population  
PT IgG antibodies were presented as geometric mean concentrations (GPs) with 
95% CIs. As the PT IgG ELISA calibration curve was linear between 5 and  
174 IU/mL, the arbitrary PT IgG cutoff values were given as 2.5 IU/mL and 
175 IU/mL, respectively, to calculate the GMC. 
The antibody levels were further divided into four categories as follows:  
≥ 125 IU/mL: very high, suggesting pertussis infection or immunisation in the 
preceding 6 months; 62.5 to < 125 IU/mL: high, suggesting pertussis infection/ 
immunisation in the preceding 7–12 months; 5 to < 62.5 IU/mL: mid-range, 
suggesting exposure to pertussis infection or immunisation > 12 months pre-
viously; < 5 IU/mL: undetectable (93, 95, 96, 204).  
Associations between age groups and GMC were assessed using the 
Kruskal-Wallis’ test; pairwise comparisons between age groups were made 
using Mann-Whitney’s U test. A chi-squared test or Fisher’s exact test was used 
to test whether the prevalence of the specified PT IgG values was associated 
with age group. The prevalence of different PT IgG values among age groups 
was further compared by a two-proportions z-test if the chi-squared test or 
Fisher’s exact test showed a statistically significant association. 
 
 
4.5.3. Calculation of estimated incidence of pertussis 
Estimated incidence of pertussis infection was calculated only for people not 
recently immunised aged 9–14 years and ≥ 20 years in seroprevalence studies. 
A cutoff level of 62.5 IU/mL was chosen (93), and the average time for the very 
high PT IgG after infection to decrease to 62.5 IU/mL was expected to be  
208.9 days (95% Cl 195.4–223.3) (203). The estimated yearly incidence was 
calculated as described by de Melker et al. (203) as 365.25/208.9 × the per-
centage of the population sera containing PT IgG of at least 62.5 IU/mL. 
Estimated incidence rates of infection were compared using a chi-squared 
test. Adjustments for multiple testing were made using the Holm-Bonferroni 
method. 
 
4.5.4. Analysis of data in a study of coughing patients 
Patients with persistent cough were analysed in three groups: pertussis, para-
pertussis, and cough of another or unknown aetiology. All analyses were per-
formed for the whole cohort and separately for children and adults. In addition, 
the prevalences of pertussis and parapertussis were calculated separately for five 
age groups (< 1y – infants, 1–9y – younger children, 10–17y – older children, 
18–64y – adults, and ≥ 65y – elderly). 
Patients’ symptoms were categorised as basic (paroxysms, inspiratory 
whoop, posttussive emesis, apnoea, and fever) and additional (other complaints 
submitted to doctors). 
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To describe patients with pertussis, parapertussis, and cough of another or 
unknown aetiology, the arithmetic means (± standard deviation [SD]) were 
evaluated for numerical variables such as age and number and duration of 
symptoms. For categorical binary demographic and personal characteristics 
such as age group, gender, hospitalisation, immunisation, etc. and for presence 
of symptoms, prevalence (with 95% CI) was evaluated. For pairwise com-
parison of study groups, the Wilcoxon and Fisher’s exact tests were used in 
cases of numerical and categorical variables, respectively. Odds ratio (OR) with 
95% CI: was calculated for all categorical variables.  
To evaluate common patterns among the five basic symptoms and three 
diagnoses (pertussis, parapertussis, and cough of another or unknown aetio-
logy), multiple correspondence analysis [MCA] was performed. The sensitivity, 
specificity, area under the receiver operating characteristic (ROC)-curve, posi-
tive likelihood ratio, and negative likelihood ratio were used to estimate the 
accuracy of the WHO’s clinical case definition of pertussis (109) and the diag-
nostic accuracy of basic symptoms. Multiple logistic regression analyses were 
performed to look for alternative predictive models of pertussis.  
 
4.6. Ethics 
All study protocols have been approved by the Research Ethics Committee of 
the University of Tartu. For seroprevalence studies, informed consent was not 
considered necessary because there were no interventions and all sera were 
collected and analysed anonymously. After complementary approval by the 
Research Ethics Committee of the University of Tartu for seroprevalence study 
in adults, the GPs informed us about coughing episodes of patients at least 20 
years old with PT IgG ≥ 62.5 IU/mL. For the study of coughing patients, all 
patients and/or their parents or guardians, as appropriate, gave their signed 
informed consent.  
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5. RESULTS AND DISCUSSION 
5.1. Participants 
A total of 5,027 subjects were enrolled across all studies, 4,478 to the seropre-
valence studies (1,053 and 3,425 to the studies in children and adults, respec-
tively) and 549 to the study of coughing patients (Table 12). 
 
 
Table 12. Demographic data of the studies 
Characteristics 
Seroprevalence 
studies 
(n=4,478) 
Study of  
coughing patient 
(n=549) 
Infants – n (%) 70 (1.6) 7 (1.3) 
Children – n (%)* 1053 (23.5) 145 (26.4) 
Adults – n (%) 3425 (76.5) 404 (73.6) 
Age in years – mean (±SD) 43.6 (27.0) 35.0 (21.6) 
Male-female ratio N/A 1:2 
Male-female ratio in children N/A 1:1 
Male-female ratio in adults  1:2 1:4 
Duration in days between start of 
illness and enrolment in the study 
mean (±SD) 
median (±SD) 
N/A 
N/A 
25.7 (21.0) 
18.0 (21.0) 
Hospitalised – n (%) N/A 9 (1.6) 
N/A – not available 
* Infants are also included 
 
 
5.1.1. Participants in the seroprevalence studies 
The samples were evenly distributed between age cohorts, with a mean number 
of samples per 10-year age groups of 490 (SD±53). The 90–99-year-old group 
was an exception, with only 65 samples available (Figure 8). The male to 
female ratio for ≥ 20 years was 1:2 in all age groups. 
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5.1.2. Participants in the study of coughing patients 
The age distribution of the participants in the study of coughing patients is pre-
sented in 10-year age groups in Figure 9. The youngest patient was 24 days old, 
and the oldest 84 years. The highest number of patients was < 10-year-olds, 
which might be due to the fact that children more often have respiratory (viral) 
infections and receive medical care more often than adults (255, 256). However, 
among adults, the highest number of patients enrolled were of the group 30–39 
years old, which is consistent with data published from Korea (232). To the best 
of our knowledge, only one study covering the entire lifespan of patients with 
persistent cough to determine the prevalence of pertussis has been published 
previously (200) (Table 7).  
Consistently with other studies’ findings, more patients with persistent 
cough seek medical care in winter than in summer; therefore, 63.2% of the 
study population were enrolled during winter, from October to March (al-
together 15 months), and 36.7% in summer, from April to September (al-
together 18 months) (Figure 10). No differences occurred in enrolment between 
summers or winters of different years; however, the study period was short. The 
ECDC has reported that pertussis activity typically has no seasonal pattern, 
which is consistent with our study, in which about half of all pertussis cases 
were enrolled during summer and another half in winter (154). 
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Of all participants, nine (1.6%) were hospitalised in the study of coughing 
patients. The highest hospitalisation rate was among infants, at 4/6 (66.6%). 
Among 1–9-year-olds, 5/107 (4.7%) were hospitalised. In other age groups, no 
one was hospitalised. 
Patient flow according to diagnosis and diagnosis confirmation method are 
presented in Figure 11.  
 
 
 
Figure 11. Study outline and patient flow in a study of coughing patients 
All patients (n=549) with acute persistent cough of unknown aetiology that had 
persisted for at least 7 days with no tendency of recovery were included as participants. 
 
 
The mean and median duration of cough before enrolment were 25.7 and 18.0 
days, respectively (Table 12). Yaari et al. have reported that the mean coughing 
duration before the enrolment in their study was similar at 23±15 days (257). In 
other previously conducted studies, median duration of cough before enrolment 
has varied from 14 to 24 days (113, 201, 226, 232).  
 
 
  
Enrolled subjects (n=549)
Patients 
with 
pertussis 
(n=22)
PCR-confirmed 
(n=4)
Culture and 
PCR-confirmed 
(n=1)
Quantitative
serology-
confirmed 
(n=17)
Patients 
with para-
pertussis 
(n=7)
PCR-
confirmed 
(n=5)
and 
PCR-
confirmed 
(n=2)
Patients with 
cough of 
another or 
unknown 
aetiology 
(n=520)
Culture
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5.2. GMC of PT IgG in entire population 
The GMC of PT IgG of the entire cohort was low at 5.9 IU/mL (95% CI: 5.7–
6.1) (Figure 12). This is comparable to the findings of studies conducted in 
Gambia and Thailand (both in the wP era), which found 4.9 IU/mL (95% CI: 
4.1–5.8 IU/mL) and 5.8 IU/mL (95% CI: 5.3–6.4) (244, 258). Interestingly, the 
GMC in two Italian studies, a study conducted in Australia in 1997–1998, and a 
study in China in 2010 showed numerically higher GMC of PT IgG at 19.2 IU/mL, 
16.3 IU/mL, 18.8 IU/mL, and 14.2 IU/mL, respectively (94, 206, 247, 250). 
These differences may be real, but could also have been caused by use of 
ELISA tests with different sensitivities and specificities (91). In addition, stu-
dies conducted in different regions at different time periods might be influenced 
by the cutoff value used, timing of the study during the natural cycle of pertus-
sis, immunisation coverage, vaccine type, and immunisation schedule (152).  
In our study, the GMC of PT IgG was higher in younger age groups at the 
time of the primary immunisation and first booster dose, after which a sharp 
decline was observed from age 3 onwards (Figure 12). Similar GMC changes 
were reported by Rota et al. in Italy and Socan et al. in Slovenia, both of which 
countries were using aP vaccines similar to those in our study (207, 247). 
However, in a study conducted in China (where both aP and wP are in use), the 
GMC tends to be higher in subjects at least 13 years old than among younger 
children (206). Because in China, the immunisation schedule consists of pri-
mary immunisation and a single booster dose at 18–24 months old, this higher 
prevalence in older children might be an indication of waned vaccine-induced 
immunity leading to increased prevalence of natural pertussis infection (206). 
The high peaks of GMC of PT IgG among infants (primary immunisation) 
and at the time of the first booster dose were seen exactly at these ages (3–11 
months and 2 years). Interestingly, the expected increased levels of GMC of PT 
IgG linked to the second and third booster doses (at the ages of 6–7 years and 
15–17 years) actually occurred one to two years later at the ages of 7–8 years 
and 18–19 years. Furthermore, there was a trend of antibody response to 
immunisations and booster doses, with GMC of PT IgG being significantly 
greater in younger age groups (3 months–1 year and 2 years) than in older age 
groups (7–8 years and 18–19 years), with 24.0 IU/mL (95% CI: 18.2–31.5) and 
11.2 IU/mL (95% CI: 9.2–13.6), respectively (p<0.001). The higher rate of 
GMC of PT IgG in the younger age group might be due to repeated doses or the 
specifics of the immune system in different age groups. 
Among subjects aged at least 20 years, the GMC of PT IgG of 3.9 IU/mL 
(95% CI: 3.6–4.2) among 40–49-year-olds was significantly lower than the 
GMC of PT IgG of other 10-year age groups, except 30–39-year-olds (Figure 
12). 
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5.3. Seroprevalence  
of PT IgG antibodies in entire population 
Of all studied subjects, 25 (0.6%; 95% CI: 0.4–0.8%) had PT IgG over the 
highest detectable level (174 IU/mL), with more than half (55.6%; 95% CI: 
54.2–57.1%) under the detectable level (Figure 13). The prevalence of an 
undetectable level of PT IgG in our study is slightly higher than in studies 
conducted in other countries, in which it has varied from 11.5% (95% CI: 8.4–
14.7%) in Slovenia in 2000 to 38% (95% CI: 36–40%) in Australia in 2007 
(204, 207). As discussed above, the use of different ELISA kits in measuring 
PT antibodies may explain differences between studies, and one cannot 
conclude that PT IgG antibody level is different in different countries. In our 
study, the highest rates of undetectable levels of PT IgG were among 40–49-
year-olds (74.4%; 95% CI: 70.0–78.4%) and 12- to 14-year-olds (72.0%; 95% 
CI: 64.6–78.7%). However, very few subjects in these age groups had antibody 
levels indicative of recent infection, suggesting that despite low antibodies, 
these age groups are rather well protected against infection. This confirms that 
the protective value of PT IgG is not clearly established. Storsaeter et al. have 
shown that 47% of those making household contact with B. pertussis with PT 
IgG levels < 2 IU/mL developed cough, compared to 15% of those with PT IgG 
levels from 2–35 IU/ml (p<0.00001) (259). If to the low PT level the criteria of 
“no history of previous pertussis or pertussis immunisation” were added then 
the risk of symptomatic pertussis raised to 71% (p=0.0007) (259). Campbell et 
al. have suggested that undetectable antibodies may be an indicator of increased 
susceptibility to pertussis at the population level (204). 
A total of 1.0% (95% CI: 0.8–1.4%) of subjects studied had PT IgG 
concentration at a very high level (Figure 13). A similar prevalence of PT IgG  
≥ 125 IU/mL has previously been reported in the Netherlands (203, 245), Israel 
(208), Denmark (249), and Italy (247), while a very high percentage (21.8%) of 
subjects with PT IgG > 125 IU/mL was reported in Mexico (251). 
When comparing the 10-year age groups, the highest percentage of subjects 
with very high PT IgG concentration were children aged 0–9 years (likely 
because of their recent immunisations), followed by young adults (20–29 years 
old) (Table 13). The highest percentage of subjects with high antibody con-
centration was similarly among 0–9-year-old children, followed by 90–99-year 
olds (Table 13). While high rates among 0–9-year olds could be explained by 
recent immunisations, the high rate of PT IgG among very old people is not 
well understood. 
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Figure 13. Distribution of subjects with different PT IgG levels 
 
 
Table 13. Distribution of subjects with different PT IgG values in percentage by 
10-year age group 
 
Age group 
(years) 
% < 5 IU/mL 
(undetectable) 
% 5 to  
< 62.5 IU/mL 
(mid-range) 
% 62.5 to  
< 125 IU/mL 
(high) 
% ≥ 125 IU/mL 
(very high) 
0–9 37.8 51.7 7.8 2.7 
10–19 60.5 33.5 4.0 2.0 
20–29 59.9 33.9 4.7 1.6 
30–39 62.8 34.6 2.1 0.4 
40–49 74.4 23.3 2.1 0.2 
50–59 59.6 38.6 1.4 0.4 
60–69 52.4 45.1 2.1 0.4 
70–79 50.5 45.6 3.1 0.8 
80–89 50.5 45.7 3.3 0.4 
90–99 41.5 52.3 6.2 0.0 
  
 
  
55.6%39.7%
3.6%
1.0%
<5 IU/mL 5–<62.5 IU/ml 62.5–<125 IU/ml ≥125 IU/ml
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Children had significantly lower prevalence of PT IgG in undetectable levels 
(48.7%; 95% CI: 45.7–51.6%) than adults (58.1%; 95% CI: 56.4–59.8%), 
p<0.001. At the same time, children had significantly higher prevalence of high 
(6.0%; 95% CI: 4.7–7.5%) and very high (2.3%; 95% CI: 1.6–3.4%) rates of PT 
IgG than adults (2.7%; 95% CI: 2.2–3.4% and 0.6%; 95% CI: 0.4–0.9%, 
respectively) (p<0.001 in both categories). However, if we compare ≥ 20-year-
olds to the children not recently immunised (ages 9–14), the prevalence for all 
categories is similar (Table 14). This suggests that pertussis immunisation 
influences the concentration of PT IgG antibodies. 
 
 
Table 14. Distribution of PT IgG values in percentage in not recently immunised 
children and adults 
 
9–14y 20–99y p 
% < 5 IU/mL 60.5 58.1 0.4 
% 5 to < 62.5 IU/ml 35.9 38.6 0.3 
% 62.5 to < 125 IU/ml 2.7 2.7 1.0 
% ≥ 125IU/ml 0.9 0.6 0.5 
 
 
Among children, the highest percentage of subjects with significantly increased 
PT IgG antibody concentrations was seen in the age cohorts following immu-
nisation, at the ages of 3 months to < 1 year, 2 years, 7–8 years, and 18–19 
years (Figure 14). Accordingly, the lowest number of subjects with undetectable 
concentrations was observed at the age of 2 years (12.3%; 95% CI: 5.5–22.8%). 
Grouping children into frequently and less frequently immunised (e.g. below 
and above age 10) groups, it appeared that a significantly higher percentage of 
those aged 10 to 19 years had undetectable antibody levels than those from 3 
months–9 years (60.5%; 95% CI: 56.3–64.7% and 38.1%; 95% CI: 34.1–42.2%, 
respectively [p<0.001]), suggesting that after immunisation, the concentration 
of PT IgG antibodies increases, but sharp decline occurs soon thereafter. 
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Among ≥ 20-year-olds, the highest prevalence of very high antibodies was 
among people of childbearing age (20–39 years old), with similar distribution 
among females 55.6% and males 33.3% (p=0.9). De Melker et al. have reported 
the highest prevalence of high and very high levels of PT IgG among 20–24-
year-olds in the Netherlands (203). 
 
 
5.4. Estimated incidence of pertussis infection based on 
seroprevalence studies and gap between estimated and 
reported pertussis 
Based on serology, there were 123 subjects (3.4%; 95% CI: 2.8–4.0%) in not 
recently immunised cohorts (children 9–14 years and adults from 20 years 
onwards) with a PT IgG concentration of at least 62.5 IU/mL. Taking this as an 
evidence of recent infection, we estimated the incidence of B. pertussis 
infection in the year before serum sampling at 5.9% (95% CI: 4.9–7.0%). This 
is consistent with similar studies: 6.6% in the Netherlands (203) and 2.4% in 
Israel (208). Kretzschmar et al. have estimated pertussis infection incidence 
rates based on seroepidemiology in five Western European countries using two 
different methods and found similar figures to ours (25). 
As the prevalence of high and very high levels of PT IgG was high among 
young adults 20–29 years old, the estimated incidence rate was also higher in 
this age group (11.0%; 95%: CI: 7.4–15.6%) than in other age groups, being 
significantly higher when compared to that of 50–59-year-olds (3.2%; 95% CI: 
1.5–6.0%) (p=0.036) (Figure 15). Furthermore, in a Dutch study, young adults 
aged 20–24 years had numerically higher estimated incidence of pertussis 
infection than other age groups, whereas in Israel, the highest peaks were 
observed among 15–19-year olds and those over 60 years (203, 208).  
Another increase in estimated pertussis infection incidence, similar to that in 
Israel (208), was observed from age 60 years onwards (Figure 15). In the 
Netherlands, however, the estimated incidence of pertussis infection was lower 
among subjects over 60 years than among those between the ages of 25 and 59 
years old (203). 
While in all age groups older than 20 years, the estimated incidence of 
pertussis was higher than that reported among 9–14-year-olds it was an opposite 
(Figure 15). In Estonia the reported incidence of pertussis in children has almost 
always been higher than in adults (data from Health board of Estonia). 
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5.5. Prevalence of pertussis in patients with  
persistent cough 
Of 549 recruited patients, 22 had pertussis (prevalence of 4.0%; 95% CI: 2.5–
6.0%). This prevalence is very similar to that found in a recent study of GP 
practices throughout Europe, with a reported prevalence of 3.0% (95% CI: 3.5–
3.7%) (202). However, our study included both hospitalised and ambulatory 
patients. Nevertheless, when comparing the prevalence of pertussis in different 
studies of coughing patients, we noticed wide variations (from 2–37%) (112, 
113, 201, 202, 220, 222, 223, 227) and that the prevalence in our study is at the 
lower end in the context of previous studies (Table 7). This could partly be 
explained by methodology: enrolling only laboratory-confirmed cases, using 
single-sample serology, and conducting the study between epidemic peaks but 
in a country with a high child immunisation rate and in which adolescent 
immunisation was introduced in 2012.  
The prevalence of pertussis was higher among children than adults (7.6%; 
95% CI: 3.9–13.2% and 2.7%; 95% CI: 1.4–4.8% respectively) (p=0.027). The 
highest prevalence of pertussis was 50.0% among those aged < 1 year. How-
ever, it is important that four of six of those patients were recruited by hospitals 
rather than in ambulatory settings. In many epidemiological studies, which are 
based on nationally reported figures, the highest incidence has been reported 
among children less than one year old (190, 191, 210, 212). This could be ex-
pected in the vaccine era, without maternal pertussis immunisation; because of 
waned immunity in adults, there are no antibodies transmitted through the 
placenta, and infants’ immunisation schedules have not yet started or are in-
complete. 
The vast majority of pertussis cases were diagnosed by clinical findings and 
positive serology (17/22 cases) in our study (Table 15). This is consistent with 
clinical practise in Estonia (Figure 3) but differs from the study conducted in 12 
EU countries, in which the majority of cases were confirmed by PCR (202).  
 
 
Table 15. Overview of laboratory methods confirming pertussis and parapertussis 
 
Diagnosis method Pertussis (n=22) Parapertussis (n=7) 
Culture 0 0 
PCR 4 5 
Culture + PCR 1 2 
Serology 17 0 
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As shown in Table 16, patients with pertussis were younger and more often 
male than those with cough of another or unknown aetiology. Patients with 
pertussis were more likely to have been hospitalised than those with a cough of 
another or unknown aetiology or caused by to parapertussis (Table 16). 
The median time between patients’ last immunisations with pertussis vaccine 
and the onset of pertussis was 2.2 years (interquartile range [IQR] 1.8–7.1) 
among children with known immunisation status. In a study conducted during 
the pertussis outbreak in a preschool in the USA, the reported average time 
between the last immunisation and start of illness was in the similar range of 22 
months (260).  
 
 
Table 16. Characteristics of patients with pertussis, parapertussis, and cough of 
another or unknown aetiology 
 
 Pertussis  
(n=22) 
Para-
pertussis
(n=7) 
Cough of 
unknown 
aetiology 
(n=520) 
Pertussis 
compared to 
unknown 
aetiology 
Parapertussis 
compared to 
unknown 
aetiology 
Pertussis 
compared to 
parapertussis 
 Mean (±SD) p-value  
Age (years) 21.6 (17.2) 
12.0 
(12.5) 
35.9  
(21.5) 0.003 0.006 0.161 
 Number of patients  
(prevalence %) 
Odds ratio  
(95% CI) 
Children  
(< 18 years old) 11 (50.0) 6 (85.7) 128 (24.6)
3.1  
(1.2–7.8) 
18.3  
(2.5–417.4) 
0.2  
(0.0–1.6) 
Male 12 (54.5) 5 (71.4) 146 (28.1) 3.1  (1.3–7.3) 
6.7  
(1.3–45.7) 
0.5  
(0.1–3.5) 
Hospitalised 3 (13.7) 1 (14.3) 5 (1.0) 16.0  (3.1–70.6) 
16.9  
(0.6–162.1) 
1.0  
(0.1–28.5) 
Immunised  
1–5 years ago 4 (18.2) 4 (57.1) 98 (18.8) 
1.0  
(0.3–2.8) 
5.7  
(1.2–29.4) 
0.2  
(0.0–29.4) 
Statistically significant differences are presented in boldface. 
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5.6. Prevalence of parapertussis in patients with  
persistent cough 
Only seven cases of parapertussis were confirmed in patients with persistent 
cough, and six of them were among children. Therefore, the overall prevalence 
of parapertussis is lower (1.3%; 95% CI: 0.5–2.6%) than the prevalence of 
pertussis. Similar to that of pertussis, the prevalence of parapertussis was higher 
among children (4.1%; 95% CI: 1.5–8.8%) than adults (0.3%; 95% CI: 0.0–
1.4%) (p=0.003). All parapertussis cases were diagnosed using PCR. 
Patients with parapertussis were younger and more often male than those 
with cough of another or unknown aetiology (Table 16). 
 
 
5.7. Clinical characteristics and course of pertussis and 
parapertussis in the era of immunisations 
5.7.1. Cough in subjects with very high and  
high concentrations of PT IgG  
Based on the seroprevalence study in adults, 111 subjects at least 20 years old 
had PT IgG ≥ 62.5 IU/mL, indicating pertussis infection during the last 12 
months. Data about visits to GPs within the previous six months were available 
for 80 subjects. Of these, 25 (31.3%) had complained of a cough to their GP. 
The percentage of subjects with cough was similar in all 20-year age groups 
(Figure 16). No pertussis was suspected or diagnosed in these subjects. In a 
study conducted in the Netherlands, the prevalence of patients with cough over 
the past year of serum sampling among subjects with PT IgG ≥ 62.5 IU/mL was 
slightly lower at 17% in 1995–1996 and 25% in 2006–2007 (245). 
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Figure 16. Distribution of subjects with PT IgG ≥ 62.5 IU/ml and their coughing 
complaints to their GPs 
31.3% of all subjects had complained of a cough to their GPs. Red indicates subjects who 
had complained of a cough to their GP, and blue sections indicate those who did not. 
 
5.7.2. Clinical characteristics and course of pertussis and 
parapertussis in patients with persistent cough 
As presented in Table 17, patients with pertussis, parapertussis, and cough of 
another or unknown aetiology had all basic symptoms, except for apnoea in 
patients with parapertussis at time of enrolment. However, patients with per-
tussis had significantly more inspiratory whooping and posttussive emesis than 
those with coughs of another or unknown aetiology (Table 17). In a meta-ana-
lysis on clinical characteristics of pertussis-associated cough based on 53 pa-
pers, the presence of inspiratory whooping and posttussive emesis was highly 
specific to pertussis, although with low sensitivity (240). 
All patients with pertussis had at least one basic symptom in addition to 
cough, and the overall number of basic symptoms was significantly higher 
among patients with pertussis than among those with a cough of another or 
unknown aetiology (Table 18). The highest mean number of paroxysms in 24 
hours was reported from patients with parapertussis. However, patients with 
parapertussis reported a milder cough on a numeric scale than other patients.  
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To determine the complex of symptoms to distinguish pertussis from other 
causes of cough, we conducted the MCA (Paper III, Figure 1), which revealed 
that in children and adults, the most remarkable result is the relatively small 
proportion of overall variability described by the first two dimensions (36.4% 
and 48.0% for children and adults, respectively). This suggests a lack of com-
mon patterns among different symptoms and diagnoses. However, as the 
patterns discovered are the most common, we can still conclude that adults with 
pertussis most often had inspiratory whooping, posttussive emesis, and apnoea, 
while children had the above plus fever. Children with parapertussis formed a 
separate group, but the analysis did not reveal any common pattern of symp-
toms related to parapertussis, which is also the reason why omitting patients 
with parapertussis changed the results very little. 
The mean (±SD) durations of a cough among patients with pertussis and 
with parapertussis were similar at 104.1 (±52.5) days and 78.3 (±62.9) days, 
respectively (p=0.194). In the case of pertussis, there were no differences in the 
mean (±SD) duration of cough between children and adults at 103.2 (±64.4) and 
105.0 (±40.3) days, respectively.  
Two significant differences between the courses of pertussis and para-
pertussis were revealed. The mean duration of paroxysms was longer in pertus-
sis patients than parapertussis patients at 5.0 (±3.9) and 1.9 (±4.5) weeks, re-
spectively (p=0.012), and the mean duration of inspiratory whooping was 
longer among pertussis patients than parapertussis patients at 3.7 (±4.5) and 0.0 
(±0.0) weeks, respectively (p=0.012). All patients recovered. 
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5.7.2.1. Clinical characteristics of pertussis and  
parapertussis in children 
At enrolment, 90.9% and 45.5% of children with pertussis had paroxysms and 
posttussive emesis, respectively. Respective numbers in parapertussis were 
100% and 33%. As shown in Table 19, there were no differences in the pre-
valence of basic symptoms between children with different diagnoses. How-
ever, children with parapertussis tended to have more paroxysms in 24 hours 
than children with pertussis or cough of another or unknown aetiology (Table 
19; Table 20). In some studies, conducted in children, the prevalence of inspi-
ratory whooping and/or posttussive emesis has been higher among children with 
pertussis than those with cough of another or unknown aetiology (114, 220). 
 
 
Table 19. Prevalence and odds ratio of basic clinical characteristics in children 
with pertussis, parapertussis, and cough of another or unknown aetiology 
 
Children 
with 
pertussis 
(n=11) 
Children 
with para-
pertussis 
(n=6) 
Children 
with cough 
of unknown 
aetiology 
(n=128) 
Pertussis 
compared 
to 
unknown 
aetiology 
Parapertussis 
compared to 
unknown 
aetiology 
Pertussis 
compared 
to para-
pertussis 
 Number of patients (prevalence %) Odds ratio (95% CI) 
Paroxysms 10 (90.9) 6 (100.0) 110 (85.9) 1.6  (0.2–75.6) N/A N/A 
Inspiratory 
whooping 4 (36.4) 3 (50.0) 31 (24.2) 
1.8  
(0.4–7.7) 
3.1  
(0.4–25.0) 
0.6  
(0.0–7.5) 
Posttussive 
emesis 5 (45.5) 2 (33.3) 36 (28.1) 
2.1  
(0.5–9.1) 
1.3  
(0.1–9.5) 
1.7  
(0.1–29.7) 
Apnoea 4 (36.4) 0 (0.0) 18 (14.1) 3.5  (0.7–15.8) N/A N/A 
Fever, 
axillary  
(> 37.3˚C) 
2 (18.2) 2 (33.3) 44 (34.4) 0.4  (0.0–2.2) 
1.0  
(0.1–7.1) 
0.4  
(0.0–9.5) 
N/A – not available 
CI – confidence interval 
Statistically significant differences (odds ratio) are presented in boldface. 
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Table 20. Mean (±SD) of characteristics and pairwise comparison of children with 
pertussis, parapertussis, and cough of another or unknown aetiology (Wilcoxon test) 
 
 Children 
with 
pertussis 
(n=11) 
Children 
with para-
pertussis 
(n=6) 
Children with 
a cough of 
unknown 
aetiology 
(n=128) 
Pertussis 
compared 
to 
unknown 
aetiology
Para-
pertussis 
compared 
to unknown 
aetiology 
Pertussis 
compared to 
parapertussis 
 Mean (±SD) p-value
Duration 
between onset of 
illness and 
enrolment in 
study (days) 
26.1 
(19.8) 29.8 (31.0) 28.7 (24.2) 0.806 0.787 0.882 
Number of  
paroxysms in  
24 hours 
6.8 (4.4) 15.0 (6.3) 9.8 (8.8) 0.941 0.015 0.023 
Severity of 
cough on a scale 
of 0–10a 
6 (2.3) 5.3 (1.0) 5.8 (1.9) 0.904 0.449 0.615 
Number of basic 
symptomsb 2.3 (1.0) 2.2 (1.2) 1.8 (1.1) 0.207 0.549 0.837 
Number of 
additional 
symptomsc 
0.5 (0.9) 0.8 (0.4) 0.8 (0.9) 0.135 0.495 0.098 
Period of 
coughing (days)
103.2 
(64.4) 82.2 (68.0) N/A N/A N/A 0.555 
N/A – not available 
SD – standard deviation 
Statistically significant differences (p-values) are presented in boldface. 
a 0 = no cough; 5 = discomfort, cough interferes with sleeping; 10 = cough is 
unbearable, very painful, constant fear of suffocation 
b Basic symptoms include paroxysm, inspiratory whooping, posttussive emesis, apnoea, 
and fever. 
c Additional symptoms are other complaints patients told their doctors. 
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5.7.2.2. Clinical characteristics of pertussis in adults 
In contrast to children, among adults, inspiratory whooping and posttussive 
emesis were significantly more characteristic of pertussis than cough of another 
or unknown aetiology (Table 21). Moor et al., in their meta-analysis on clinical 
characteristics of pertussis-associated cough, also reported that presence of 
inspiratory whooping and posttussive emesis have high specificity in adults 
(240). 
 
 
Table 21. Prevalence and odds ratio of clinical characteristics in adults with pertussis 
and cough of another or unknown aetiology 
 
Adults with 
pertussis 
(n=11) 
Adults with cough 
of unknown 
aetiology (n=392) 
Pertussis compared 
to cough of 
unknown aetiology 
 
Number of patients  
(prevalence %)
Odds ratio  
(95% CI) 
Paroxysms 11 (100.0) 328 (83.7) N/A 
Inspiratory whooping 9 (81.8) 142 (36.2) 7.9 (1.6–76.5) 
Posttussive emesis 9 (81.8) 82 (20.9) 17.0 (3.4–165.3) 
Apnoea 5 845.5) 77 (19.6) 3.4 (0.8–13.9) 
Fever, axillary (> 37.3˚C) 3 (27.3) 159 (40.6) 0.5 (0.1–2.3) 
N/A – not available 
CI – confidence interval 
Statistically significant differences (odds ratio) are presented in boldface. 
One adult patient with parapertussis was not included in statistical analysis.  
 
 
Among adults with pertussis, the number of basic symptoms was significantly 
higher than among patients with cough of another or unknown aetiology (Table 
22). 
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Table 22. Mean (±SD) of characteristics and pairwise comparison of adults with 
pertussis and cough of another or unknown aetiology (Wilcoxon test) 
 
 Adults with 
pertussis 
(n=11) 
Adults with a 
cough of 
unknown 
aetiology 
(n=392) 
Pertussis compared to 
cough of unknown 
aetiology 
 Mean (±SD) p-value 
Duration between 
onset of illness and 
enrolment in study 
(days) 
31.6 (21.7) 24.5 (19.7) 0.137 
Number of paroxysm 
in 24 hours 11.2 (11.0) 11.9 (10.0) 0.548 
Severity of cough on a 
scale of 0–10a 6.4 (2.0) 6.4 (1.7) 0.913 
Number of basic 
symptomsb 3.3 (0.9) 2.0 (1.2) < 0.001 
Number of additional 
symptomsc 0.9 (0.8) 0.9 (1.1) 0.934 
Period of coughing 
(days) 105.0 (40.3) N/A N/A 
N/A – not available 
SD – standard deviation 
Statistically significant differences (p-values) are presented in boldface. 
a 0 = no cough; 5 = discomfort, cough interferes with sleeping; 10 = cough is 
unbearable, very painful, constant fear of suffocation 
b Basic symptoms include paroxysm, inspiratory whooping, posttussive emesis, apnoea, 
and fever. 
c Additional symptoms are other complaints patients told their doctors. 
 
5.7.2.3. Pertussis in the elderly 
A total of 54 patients aged at least 65 years were enrolled in the study of 
coughing patients (composing 9.8% of all enrolled patients), but none of them 
had pertussis. However, in the seroprevalence study, we noticed that in con-
centration of PT IgG, the group of elderly people did not differ from other 
groups, and 3% of all the elderly had PT IgG of at least 62.5 IU/mL, indicating 
a recent contact with B. pertussis, and 32% of them had reported cough within 
the previous 6 months to their GPs (none of which reports were diagnosed as 
pertussis). Both findings raise questions about the clinical course of pertussis 
among the elderly.  
Ridda et al. have reviewed recent literature on pertussis in the elderly and 
have described the increase in notification rates in those aged 60 year and older 
(261). The number of epidemiological studies in this age group is limited, and 
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diagnosis is difficult because of the lack of specific symptoms (261). In a retro-
spective study conducted in the USA among those aged 50 and older, the most 
frequent initial diagnoses before pertussis diagnosis were cough and upper 
respiratory tract infection (57). However, pertussis can cause significant morbi-
dity, hospitalisation, and death among the elderly (261, 262). 
 
 
 5.8. Diagnostic value of symptoms corresponding to  
the WHO’s clinical case definition and  
basic symptoms of pertussis 
Of the 22 patients with confirmed pertussis, 17 met the WHO’s clinical case 
definition of pertussis (109), and of the 527 patients with cough of another or 
unknown aetiology or parapertussis, 201 did not meet the definition. The 
sensitivity and specificity of this definition were 0.77 (95% CI: 0.55–0.92) and 
0.38 (95% CI: 0.34–0.42), respectively (Paper 3, Table 4). Due to low sensi-
tivity and specificity, the overall prediction accuracy of the WHO’s clinical case 
definition was poor at 0.58 (95% CI: 0.49–0.67) (Paper 3, Table 4). Further-
more, the high sensitivity of the WHO’s clinical case definition, varying from 
0.79–1.00, has been reported previously; however, the specificity has been 
lower, varying from 0.15–0.17 (112-114). 
The step-wise multiple logistic regression analysis revealed that the optimal 
combination of symptoms for the entire cohort and for adults consists of inspi-
ratory whooping, posttussive emesis, and fever (prediction accuracy 0.77 [95% 
CI: 0.67–0.87] and 0.89 [95% CI: 0.82–0.97], respectively. For children, no 
multiple logistic regression model fit the data better than single symptoms. The 
sensitivity of multivariate logistic regression models did not differ from the 
sensitivity of the WHO’s clinical case definition, while the specificity and over-
all prediction accuracy of logistic regression models were higher (Paper 3, 
Table 4). 
A summary of the three statistical analyses to determine the pertussis-spe-
cific symptoms for the entire cohort, for children, and for adults is presented in 
Table 23. Inspiratory whooping and posttussive emesis in addition to cough (as 
inclusion criteria) were the symptoms which most frequently indicated per-
tussis. However, the sensitivity and specificity of these symptoms are not reli-
able enough for decision making in clinical practise. Furthermore, Ebell et al., 
in their meta-analysis, also did not find a reliable clinical decision rule (239). 
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Table 23. Summary of statistical analysis to determine pertussis-specific symptoms 
 
 
All patients with 
pertussis 
(n=22) 
Children with 
pertussis 
(n=11) 
Adults with pertussis 
(n=11) 
Prevalence of 
symptoms 
Inspiratory whooping, 
Posttussive emesis 
Not found Inspiratory whooping, 
posttussive emesis 
MCA N/A Inspiratory 
whooping, 
posttussive 
emesis, 
apnoea, fever 
Inspiratory whooping, 
posttussive emesis, 
apnoea 
Step-wise multiple 
regression analysis 
Inspiratory whooping, 
posttussive emesis, 
fever  
Not found Inspiratory whooping, 
posttussive emesis, 
fever 
N/A – not available 
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6. GENERAL DISCUSSION 
6.1. Is pertussis still an important disease in Estonia? 
Over the last ten years, the reported incidence of pertussis has varied from 3–
97/100,000 (0.003–0.097%) in Estonia. According to our study of coughing 
patients, the prevalence of pertussis is about 4%. Based on seroprevalence stu-
dies, about 6% of subjects not recently immunised have had pertussis infection 
yearly. This suggests that B. pertussis is still circulating in highly immunised 
populations with long immunisation history and in all age groups.  
It is mandatory to report pertussis to the surveillance system in Estonia. 
National surveillance systems are effective at collecting severe and classical 
cases, but mild and asymptomatic cases are not included. Seroprevalence 
studies are unique because they capture all types of pertussis infections: clas-
sical, atypical, mild, and even asymptomatic. The huge gap between reported 
and estimated incidence (based on seroprevalence studies) of pertussis indicates 
that the majority of pertussis cases are either atypical, mild, or asymptomatic 
and thus neither recognised nor reported to the official reporting systems. Mild 
and asymptomatic cases are unimportant from a clinical perspective, but they 
are important epidemiologically. Seroepidemiological studies yielding a real 
overview of the epidemiology of the disease should be conducted occasionally.  
As expected, more severe cases leading to hospitalisations occurred mostly 
among infants. The last reported death from pertussis in Estonia was in an 
infant in 2007 (data from Health Board of Estonia). Furthermore, in the other 
EU/EEA countries, mortality from pertussis is low; only 101 pertussis-related 
deaths were reported between 2006 and 2015 in these countries (11). In 2015, 
all pertussis-related deaths occurred in infants, about 90% of them in children 
under three months (263). Usually pertussis immunisation starts at the age of 2–
3 months (148). Therefore, we suggest that the vaccines currently used are 
sufficiently effective to serve their main purpose, to prevent death due to 
pertussis, at least in countries with high immunisation coverage and high levels 
of medical assistance.  
After the start of universal immunisation with pertussis vaccine, the impor-
tance of pertussis has diminished as the notification rate of pertussis (classical 
and severe cases) has significantly decreased. However, vaccines currently used 
are unable to prevent pertussis infection and mild disease. To avoid all cases of 
pertussis, a new vaccine which also prevents colonisation by B. pertussis is 
needed.  
 
6.2. Do we need pertussis immunisation in adults? 
Pertussis immunisation in adults is recommended to prevent the transmission of 
B. pertussis to unprotected younger infants, to protect adults from the disease, 
and to reduce the circulation of pertussis (264). However, as shown by Warfel 
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et al., aP vaccines currently used do not prevent colonisation and transmission 
by B. pertussis from immunised subjects to pertussis-naive subjects, at least in a 
baboon model (33). In addition, studies of postpartum immunisation and 
cocooning have shown no reduction in the prevalence of pertussis disease in 
infants of immunised parents when compared to non-immunised parents (265, 
266). Furthermore, dTap immunisation was only moderately effective to pre-
vent PCR-confirmed pertussis among adolescents and adults in the USA (267). 
As in other studies, pertussis among adults in our studies was mostly mild to 
moderate: there were no hospitalisations among adults because of severe 
pertussis in a study of coughing patients. Only 30% of adults with a high or 
very high level of PT IgG, which indicates recent pertussis, had complained of 
coughing to their GP in our seroprevalence study. In our studies, the prevalence 
of pertussis among coughing adults and the estimated incidence of pertussis 
infection among adults based on serology were relatively low at 2.7% and 5.8%, 
respectively. We believe that this rate is too low to recommend universal 
national pertussis immunisation in adults. In addition, in a study conducted in 
adolescents immunised with one dose of dTap, the effectiveness was only about 
9% by the fourth year after immunisation (137). This suggests that an effective 
immunisation schedule should include multiple doses with a high immunisation 
rate, but this is expensive and complicated to achieve. However, we should 
remember that sometimes pertussis in adults can be an uncomfortable disease 
with prolonged cough (224), and pertussis immunisation may help to prevent it 
at the individual level (267). 
Pertussis immunisation for health care worker safety and patient safety has 
been recommended (268). However, the same problems as those of pertussis 
immunisation in adults (duration of effective immunity and transmission of B. 
pertussis) persist. We are not aware of any consensus recommendation on 
pertussis immunisation of health care professionals by the ECDC; however, the 
CDC recommends a one-time dose of dTap as early as possible if not received 
previously (269). Based on the data above, the real benefit of this suggestion is 
unclear. In Estonia, no official recommendations about pertussis immunisation 
of health care workers have been published. As long as the duration of immu-
nity after immunisation is unknown, and more importantly, as long as pertussis 
vaccines are unable to prevent colonisation and transmission, we cannot 
recommend universal pertussis immunisation for health care workers. However, 
everybody can immunise themselves to prevent pertussis at the individual level.  
Pertussis is a life-threating disease mainly for unimmunised infants. In 
EU/EEA countries, primary pertussis immunisation starts at the age of 2–3 
months (148). Maternal pertussis immunisation to protect infants under this age 
has been implemented in the UK, Belgium, the Czech Republic, Greece, Ire-
land, Italy, and some regions in Spain (270). According to a recent systematic 
review, maternal pertussis immunisation during pregnancy is an effective and 
safe method to prevent disease in infants < 3 months (270). However, after 
examining epidemiological data from Estonia, we have observed a similar 
decline in pertussis cases among infants without maternal immunisation, likely 
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due to epidemiological trends (271). According to the Health Board of Estonia, 
to date fewer than three cases of pertussis have been diagnosed among children 
< 6 months old annually from 2011–2017. In addition, based on our study of 
coughing patients, the severe cases of pertussis among infants in Estonia are 
rare; therefore, at present we recommend the careful monitoring of pertussis in 
infants. Immunisation of pregnant women may be considered if the epidemio-
logical situation changes.  
Thus, we believe that implementation of universal adult pertussis immuni-
sation is not currently needed in Estonia, as the main purpose of pertussis 
immunisation (preventing death by pertussis) is achieved without it. To stop the 
circulation of B. pertussis, a vaccine which also prevents colonisation and 
grants life-long immunity is needed. 
 
 
6.3. Is the current pertussis immunisation schedule 
optimal in Estonia? 
The Estonian pertussis immunisation schedule consists of three doses of DTaP 
vaccine for primary immunisation at the ages of 3, 4.5, and 6 months and three 
booster doses at the ages of 2 years, 6–7 years (since 2008), and dTap for 15–16 
years (since 2012). This immunisation schedule offers one of the highest 
numbers of pertussis vaccine doses for children in Europe (148). However, 
there are no booster doses for adults and no recommendations for pertussis 
immunisation for specific groups, for example health care workers or pregnant 
women, in Estonia’s immunisation schedule. 
After the implementation of the second and the third booster doses, the 
notification rate of pertussis decreased to 4–5 cases per 100,000 people. As this 
low level has stood since 2012 without any observed increase, this is the longest 
low-incidence period in Estonia following re-independence (Figure 5). There-
fore, we believe that changes in the immunisation schedule in 2008 and 2012 
through implementation of additional booster doses at school entry and leaving 
has been effective in preventing pertussis. However, the decreased rate of 
pertussis may not be result only of the changing immunisation schedule. In the 
same era, improved diagnostic methods (quantitative serology and PCR in 
2012) and additional education of health care workers (for example not to 
perform serology in recently immunised children) were implemented, and it is 
difficult to assess the roles of these. In any case, reported incidence of pertussis 
in infants (in most vulnerable group) is low. The low incidence should be 
regarded as real since infants with serious pertussis cases are hospitalised and 
the disease recognised. In addition, the overall mortality rate in infants is 
minimal in Estonia, and we know the causes of infant death. 
The reasons not to implement adult and/or maternal immunisation in Estonia 
are presented above (paragraph 6.2).  
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We believe that the current pertussis immunisation schedule is effective 
enough to prevent serious cases at least in inter-epidemic years and that 
eradication of pertussis is not possible with the vaccines currently available.  
 
 
6.4. Management of patients with persistent cough  
Persistent cough is a very common reason for visiting a doctor (198, 199). 
However, the aetiology of cough is difficult to define based solely on its charac-
teristics (199). About half of all visits for cough are by children less than 15 
years of age (198). Similarly, in our study, the age group with the highest 
number of patients with persistent cough was < 10-year-olds. This might due to 
the more frequent upper respiratory tract infection among children and the fact 
that parents might worry about the health of their children more than their own 
and therefore visit doctor more readily over concerns related to them.  
The most important reason to detect the aetiology of a cough is for treatment 
and management of the patient. In addition, determination of the aetiology of a 
cough is relevant for surveillance purposes to assess the situation, interfere 
quickly if necessary, and plan future actions at the level of public health. With 
data on the aetiology of coughs and incidences of diseases, there is greater hope 
for better medications and vaccines. 
Although in our study the inclusion criteria included at least seven days of 
cough, the mean duration between start of illness and enrolment in the study was 
still 26 days, suggesting that patients seek medical care if cough persists and/or 
doctors suspect respiratory viral infection for cough of short duration. The most 
frequently described symptoms at enrolment were presence of paroxysms and 
posttussive emesis for pertussis, presence of paroxysms and inspiratory whooping 
for parapertussis, and presence of paroxysms and fever for cough of another or 
unknown aetiology. However, after conducting several statistical analyses, we 
were unable to identify pertussis-specific symptoms in this highly immunised 
population, which suggests that no symptoms are pathognomonic for pertussis. 
However, in our study we only examined classical symptoms of pertussis rather 
than all symptoms patients may have had, and other symptoms such as sleep 
disturbance and sweating should be examined more carefully.  
If the reason for cough is not revealed through careful medical-history and 
physical examination, then diagnostic tests (laboratory and imaging tests) 
should be performed. Infectious agents are easy to diagnose using PCR cough 
panels, where a majority of the important pathogens (both bacterial and viral) 
are included in one test. However, in addition to several disadvantages that PCR 
has, in Estonia the price of these panels is too high for GPs to use them 
routinely.  
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6.5. Laboratory criteria of pertussis 
As mentioned above, pertussis cannot be diagnosed based on clinical signs 
alone. Although in most countries, culture, PCR, and serology of pertussis are 
available (6), methods used vary (Figure 3). In addition, laboratory criteria 
specifically about pertussis serology vary (through quantitative vs qualitative 
tests, single- vs paired-sample serology, and different cutoff values) (6, 81). 
In our study of patients with cough, the number of patients with pertussis 
and parapertussis confirmed by PCR was unexpectedly low despite the fact that 
PCR was done in almost all patients (n=546). For example, about 80% of all 
pertussis cases are confirmed by PCR in Denmark and the USA (Figure 3) (105, 
107). We speculate that the main reason for the low number of PCR-confirmed 
cases in our study was the long duration of cough (a mean of 26 days) between 
onset of the illness and seeking medical care. The late enrolment is consistent 
with the high rate of serology-confirmed cases. If we had used the laboratory 
criteria of the CDC, which only accepts culture and PCR (111), we would have 
missed more than 75% of pertussis cases. Furthermore, in clinical practise, about 
95% of all pertussis cases are confirmed with single-sample serology in Estonia 
(data from Health Board of Estonia). Therefore, in our opinion, PT-based 
serology tests with high specificity and sensitivity should be used to detect late-
stage pertussis cases in Estonia. Results from PT IgG ELISA can be standardised 
using the WHO International Standard Pertussis Antiserum (90). The controls of 
the ELISA test used in our studies were calibrated using this antiserum (272). 
However, the exact cutoff values for both paired and single-sample serology may 
vary among studies and should be determined in the future. 
In clinical practice, the importance of B. pertussis culture has decreased 
since the introduction of PCR, mainly because of logistical reasons and the long 
duration between collection of the sample and the result. However, culture is 
still the gold standard for diagnosing pertussis and the only method for 
determining the antibiotic sensitivity of pathogen. Therefore, we recommend 
performing cultures.  
To the best of our knowledge, pertussis PCR has not yet been approved by 
the Food and Drug Administration or European Medicines Agency, which is a 
serious problem. Nevertheless, Burd has published a guideline for validation of 
laboratory-developed molecular assays for infectious diseases (273). Another 
problem is detection of B. pertussis in asymptomatic patients. For example, 
4.8% of asymptomatic Chinese schoolchildren had positive PCR to B. pertussis 
(88). Whether transmission from asymptomatic carriers to others is possible is 
still debated (274, 275). A study conducted by Warfel et al. (33) indicated that 
asymptomatic transmission is possible, and studies of postpartum immunisation 
and cocooning have shown no reduction in the prevalence of pertussis disease 
in infants of immunised parents compared to non-immunised parents (265, 
266). It is widely known that pertussis is most infectious during the catarrhal 
stage, when people do not even have severe cough and paroxysms, but B. 
pertussis is still spread via aerosolised respiratory droplets (21). However, the 
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CDC does not recommend testing asymptomatic subjects, even in cases of close 
contact with laboratory-confirmed cases, as it increases the likelihood of 
obtaining false positive results, and the decision of the post-exposure 
prophylaxis should not be based on PCR (85).  
In 2012, most medical laboratories in Estonia switched from qualitative to 
quantitative serology tests, as recommended by the EU Pertstrain group (81), as 
these contains only PT antigen specific to B. pertussis and the result is ex-
pressed in IU/mL. Previously used qualitative tests included several B. pertussis 
antigens or even whole bacteria, and cross-reactivity with other microbial 
antigens such as other Bordetella species, Haemophilus species, Mycoplasma 
pneumoniae, and Escherichia coli might occur (81). The low specificity of 
qualitative serology tests might cause false positive cases; therefore, only 
ELISAs with PT as the only antigen should be used. 
 
 
6.6. Limitations of the study 
Some limitations of our studies should be noted.  
First, the weakness of all seroprevalence studies is the indirect method of 
estimating incidence; however, this method also has the strength of being the 
only way to estimate the spread of pertussis infection at a population level.  
Second, we did not have many data about the subjects in the seroprevalence 
studies. The only information available was a subject’s age in the study in 
children and a subject’s age and gender in the study in adults. However, we 
know that none of the subjects had been diagnosed with clinical or laboratory-
confirmed pertussis. As the sera collected were medical laboratory leftovers of 
hospitalised and ambulatory patients with any diagnosis, we cannot exclude the 
possibility of selection bias towards a disproportionally sick population. 
However, Kelly et al. found no significant differences when measuring immu-
nity to five vaccine-preventable diseases in children between laboratory 
leftovers and population-based cluster sampling methods (276).  
Third, all studies were conducted in the interepidemic period. Pertussis 
incidence follows the cyclical pattern of the disease, and one cycle usually lasts 
3–5 years, indicating that our studies were conducted in low incidence years.  
Fourth, in the study of coughing patients, the planned sample size was not 
achieved. We calculated the sample size based on the cases in an extraordinary 
epidemic year (97/100,000 in 2010) in Estonia and planned to enrol 900 
subjects. During the study period, the officially reported incidence of pertussis 
dramatically declined to 4–5/100,000 per population. Therefore, enrolment was 
much slower and took much longer than expected. We suspect the notification 
rate of pertussis in the epidemic year may also have included false positive 
cases, because qualitative serology was used and almost all cases were 
confirmed using serology and occurred among children in the age groups in 
which children in Estonia are immunised with pertussis vaccine (data from 
Health Board of Estonia). The statistical requirement for sample size (pre-
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valence of pertussis with a 95% CI: ±2%) was met by 549 enrolled patients due 
to the lower prevalence of pertussis than expected. 
Fifth, we suspect that not all patients who met inclusion criteria were 
enrolled in the study of coughing patients. Doctors probably did not follow the 
study protocol. While we did not specifically study the reasons for that, we 
suspect that less severe cases were not included because of busy schedules. Due 
to a lack of resources, we were not able to use screening logs or a special trial 
nurse. In addition, we mostly investigated classical pertussis symptoms, but 
other symptoms should also be examined carefully.  
Sixth, due to resource restrictions, we were unable to evaluate other 
causative agents of coughs or monitor duration of symptoms in patients with 
cough of another or unknown aetiology in the study of coughing patients. 
However, the mean duration of acute cough has been evaluated as 18 days 
(277), and in our study the mean duration of cough before enrolment was 
already 26 days; therefore, we suspect that most viral upper respiratory tract 
infections were excluded.  
We believe that none of these limitations prevented us from drawing 
adequate conclusions. 
 
6.7. Future considerations 
Despite performing several analyses, we were unable to propose clinical criteria 
clearly superior to the WHO’s for distinguishing pertussis from other causes of 
persistent cough. Although patients with pertussis were more likely to have 
inspiratory whooping and posttussive emesis than others, the presence or ab-
sence of these symptoms did not confirm or exclude pertussis. Therefore, a new, 
more age-specific, clinical case definition is needed. The Global Pertussis 
Initiative group have published a new clinical case definition algorithm (108). 
They state that high sensitivity and good specificity should be expected with the 
presence of the triad: afebrile/low-grade fever, a paroxysmal cough that does 
not improve, and watery coryza. The addition of apnoea, seizures, cyanosis, 
emesis, or pneumonia should further increase both sensitivity and specificity 
among 0–3-month-olds (108). In older children (4 months to 9 years old), the 
addition of whooping, apnoea, and posttussive emesis should increase speci-
ficity, and in those ≥ 10 years old, the addition of sweating episodes between 
paroxysms should significantly increase specificity (108). However, these 
criteria are not validated, and this should be done in the future.  
 Pertussis symptoms among the elderly are largely unknown. As we had no 
pertussis cases among coughing patients aged 55 and older, they probably do 
not have persistent cough. Although based on the seroprevalence study, we can 
clearly state that pertussis infection occurs in the elderly with similar frequency 
to that in any other age group.  
Pertussis vaccines, which are currently used quite effectively to prevent 
severe disease and death, are not as effective as other vaccines that have stopped 
the circulations of pathogens such as smallpox, Haemophilus influenzae type B, 
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poliomyelitis, etc. Therefore, a new pertussis vaccine is needed. Immunity from 
the vaccine should last the recipient’s entire life (278) after few immunisations 
(ideally one), preferably administered by a method other than injection (279). A 
high level of effective immunity without side effects should be rapidly 
achieved, and the vaccine should prevent the disease in all age groups (in-
cluding infants and the elderly) and transmit maternal protection to the foetus 
(279). Broad protective immunity against all variants of B. pertussis at a low 
cost and easy storage requirements are also characteristics of the ideal vaccine 
(279). Most importantly, to prevent the disease, the new vaccine should also 
prevent colonisation to avoid shedding (279).  
Despite the similar pertussis vaccines and immunisation schedules in most 
European countries, the reported incidence of pertussis and its prevalence 
among coughing patients varies widely (11) (Table 7). The most important 
reason is probably the heterogeneity in methods used for laboratory confir-
mation of pertussis. Therefore, standardisation of pertussis detection and confir-
mation methods are also needed. 
In primary care, point-of-care testing of pertussis would be most useful to 
encourage GPs to check for pertussis. The test should be usable in all patients 
with the cold-like symptoms of the early stage of the disease, which would 
allow early treatment and prevent the spread of pertussis. In addition, the test 
should be usable without special equipment or user training and at a low cost 
and should yield quick results, preferably within 10 minutes, within the appoint-
ment. We are not aware of a test fulfilling this description on the healthcare 
market but recently Salminen et al. have developed a rapid lateral flow 
immunoassay for serological diagnosis of pertussis which fulfils some of the 
criteria noted above (280). 
It is still unclear how to define protective immunity against B. pertussis. 
Storsaeter et al. have shown that symptomatic pertussis is more frequently found 
among people with a low initial level of PT IgG, especially those without a 
previous history of pertussis vaccination or disease (259). Campbell et al. have 
suggested that the high prevalence of people with undetectable PT IgG may be an 
indicator of increased susceptibility to pertussis at the population level (204). 
However, the level of the protective value of PT IgG has not been established. 
Therefore, different authors have used different levels of PT IgG to assess the 
number of subjects with seroprotection. Most authors have used < 5.0 IU/mL as 
negative sera (93, 96, 204, 205). Some authors have used the cutoff value of  
> 10 IU/ml as seroprotection based on the lowest measured antibody titre among 
children recovering from pertussis (208, 281). Zhang et al. have used the 
Virion/Serion anti-PT IgG Elisa kit and, following the instruction of the kit’s 
manual, considered subjects bearing more than 30 IU/mL of IgG against PT 
seropositive, with below 20 IU/mL considered seronegative (206). However, 
recent studies have demonstrated that in addition to humoral immunity, cellular 
immunity has an important role in ensuring immunity against B. pertussis (33). 
As far as we now, there is still no single reliable marker for evaluating immunity 
against B. pertussis at both the population and individual levels.  
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7. CONCLUSIONS 
The reported pertussis incidence has dramatically decreased (from 97/100,000 
in 2010 to 4.3/100,000 in 2017) during our studies in Estonia. Over the last five 
years, the reported incidence has been stable at 4–5/100,000. This is the longest 
low reported incidence period since the re-independence of Estonia. Further-
more, infants are well protected; the last death due to pertussis was in 2007, and 
in the last five years, fewer than 3 cases have been diagnosed in this age group 
each year. Similarly, in our study of coughing patients, the prevalence of per-
tussis was low, which suggests that the current pertussis immunisation schedule 
is sufficiently effective in controlling pertussis disease, at least between 
epidemics. However, the large gap between reported and estimated incidence of 
pertussis indicates that B. pertussis is still circulating and is mostly asympto-
matic or mild in the vaccine era. The eradication of pertussis requires a new 
vaccine which also prevents colonisation of B. pertussis. 
 
The following specific conclusion can be drawn from this research:  
1.  The population GMC of PT IgG is low in Estonia. Higher levels of GMC of 
PT IgG were detected at the ages of pertussis immunisation according to the 
Estonian immunisation schedule. However, sharp decline of GMC of PT IgG 
already occurs in the first year following immunisation. This suggests that 
serologic methods are not reliable for diagnostic purposes when the last 
pertussis immunisation occurred during the last year.  
Although the majority of study subjects had PT IgG at undetectable 
levels, a very few had antibodies at high or very high levels, indicating 
recent B. pertussis infection. This suggests that despite the low level of anti-
bodies, people are well protected against pertussis, and factors other than 
antibodies play an important role in ensuring protection against the disease. 
Thus, antibody measurement cannot be used to characterise population pro-
tection levels against pertussis.  
2.  The estimated incidence of pertussis based on serology occurred in similar 
frequencies in all adult age groups and children not recently immunised. 
This indicates permanent circulation of B. pertussis in the Estonian popu-
lation and that current vaccines are ineffective to stop that circulation.  
3.  The estimated incidence of pertussis infection based on PT IgG was about 
500 times greater than the officially reported incidence of pertussis disease. 
This suggests that pertussis is mostly mild or asymptomatic in immunised 
subjects or pertussis symptoms are unknown and thus poorly recognised.  
4. The prevalence of pertussis among coughing patients is low in Estonia. The 
highest prevalence of pertussis, among infants, is associated with absent or 
incomplete immunisation in this age group. The absence of confirmed cases 
of pertussis among those at least 65 years old with cough indicates that an 
asymptomatic course or symptoms other than cough are specific to pertussis 
in this age group. The overall low prevalence indicates that the pertussis 
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vaccine and immunisation schedule currently used are sufficient to reduce 
symptomatic pertussis to a minimal level in inter-epidemic periods at 
present. The prevalence of parapertussis among coughing patients was even 
lower than the prevalence of pertussis.  
5.  No parapertussis-specific symptoms were revealed in the study of coughing 
patients. Although patients with pertussis had inspiratory whooping and 
posttussive emesis more often than patients with cough of another or un-
known aetiology, the sensitivity and specificity of classical symptoms of 
pertussis is low in the highly immunised population. New, age specific 
clinical criteria could improve the overall prediction accuracy of the WHOʼs 
clinical case definition of pertussis.  
6.  Symptomatic pertussis and parapertussis result in long-lasting cough, even in 
the vaccine era. However, the mortality of pertussis in developed countries 
with high immunisation coverage and a high level of medical assistance is 
extremely low.  
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9. SUMMARY IN ESTONIAN 
Läkaköha epidemioloogia ja sümptomid Eestis 
Läkaköha on klassikaline lastehaigus, mida kirjeldas esmaskordselt Guillaume 
de Baillou 1578. aastal kui raske köhaga kulgevat ja kõrge suremusega haigust 
4- kuni 10-kuuste laste hulgas (29). Haigus on põhjustatud Gramm-negatiivse 
bakteri Bordetella pertussise poolt, mis isoleeriti 1906. aastal kahe prantsuse 
teadlase Jules Bordet and Octave Gengou poolt Pasteur instituudis Pariisis (32). 
Vastavalt Maailma Tervishoiuorganisatsiooni (MTO) läkaköha kliinilisele 
definitsioonile on läkaköha vähemalt 14 päeva kestev köhaga haigestumine, 
millele lisandub vähemalt üks järgmistest sümptomitest: paroksüsmaalsed köha-
hood, inspiratoorseid repriisid või köhahoojärgne oksendamine (109). Täna-
päeval esineb MTO definitsioonile vastavat klassikalist läkaköha suhteliselt 
harva, peamiselt vaid mittevaktsineeritud laste hulgas (52). Teismelised ja täis-
kasvanud, kes on läkaköha antigeenidega varem kokku puutunud, kas siis eel-
neva vaktsineerimise või haiguse läbipõdemise teel, kuid kelle immuunsus on 
vananenud, põevad haigust kergemini. Tavaliselt kulgeb neil läkaköha 1–2 
nädalat kestva mitteparoksüsmaalse köhana või põevad nad täiesti asümp-
toomselt. Viimasel juhul esineb B. pertussise kandlus ninaneelus ning inimene 
on nakkusohtlik (3) kuid ise täiesti vaevusteta. Imikutel on haiguse kulg kõige 
raskem koos apnoede, tsüanoosihoogude ja bradükardiaepisoodidega (41).  
Kuna tänapäeval võivad nii läkaköha kulg kui ka sümptomid olla väga eri-
nevad, siis tuleb läkaköha diagnoosi kinnitamiseks või välistamiseks kasutada 
laboratoorseid meetodeid. Mikroobi väljakülvamine on kuldne standard ja 
ainuke meetod, mis võimaldab määrata bakteri antibiootikumtundlikkust, kuid 
madala tundlikkuse ning kuni 10-päeva pikkuse diagnoosi kinnitumise aja tõttu 
on see meetod harva kliinilises praktikas kasutusel (20). PCR meetod on suure-
ma tundlikkusega ja oluliselt kiirema diagnoosi kinnitumise ajaga kui mikro-
bioloogiline väljakülv ja seetõttu enam kasutatav kliinilises praktikas, kuid B. 
pertussise tuvastamiseks kasutatavad praimerid ei ole veel standardiseeritud 
(20). Eestis on siiani läkaköha diagnoosimiseks enamasti kasutatud seroloogilisi 
meetodeid. MTO soovitab kasutada paarisseerumite meetodit, mille kohaselt on 
läkaköha diagnoosi kinnituseks vajalik oluline antikehade kontsentratsiooni tõus 
kahes vähemalt kahe nädalase vahega võetud vereanalüüsis (109). Selle meetodi 
puuduseks on samuti diagnoosi hilinemine. Seetõttu kasutatakse kliinilises prak-
tikas enam ühekordse seroloogia meetodit, mis annab võimaluse haiguse diag-
noosi kinnitada ka haiguse hilises faasis, kui PCR ja külv ei ole enam infor-
matiivsed (20). Samas, seroloogiat ei saa kasutada inimestel, kes on läkaköha 
vastu vaktsineeritud viimase aasta jooksul ning teiseks meetodi puuduseks on 
valideerimata diagnostilised piirväärtused (20). 
Arenenud riikides hakati läkaköha vastu vaktsineerima 1950. aastatel. 
Vaktsineerimine oli efektiivne ning haiguse avaldumus (incidence) langes möö-
dunud sajandi 70–80. aastatel enam kui 90% võrreldes vaktsineerimiseelse 
ajaga (5). Viimastel aastakümnetel on läkaköha avaldumus oluliselt tõusma 
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hakanud ning läkaköha on tänapäeval kõige enam levinud vaktsiinvälditav hai-
gus ka nendes riikides, kus läkaköha vaktsiiniga hõlmatus on kõrge (5). Ka  
Eestis on riiklikult registreeritud läkaköha avaldumuse trendid sarnased teiste 
kõrge immuniseerimistasemega riikidega (11). Kui 1970. ja 1980. aastatel oli 
läkaköha avaldumus ~4–5/100 000 elaniku kohta siis alates taasiseseisvumis-
ajast on avaldumus oluliselt tõusnud ning 2010. aastal registreeriti Eestis 
läkaköha 97 juhtu 100 000 elaniku kohta (11). See oli kõrgeim aastane läkaköha 
avaldumus Euroopas (11). 
Eestis ei olnud enne käesolevate uuringute alustamist teada tegelikku läka-
köhasse haigestumist järgmistel põhjustel: 
1) Kuni 2012. aastani olid Eestis kasutusel ainult kvalitatiivsed seroloogilised 
testid. Nende testide puuduseks oli madal spetsiifilisus, st. need andsid ristre-
aktsioone teiste tekitajatega ja seega ka valepositiivseid vastuseid. Alates 
2012. aastast on enamikus Eesti laborites kasutusel kõrge tundlikkuse ja 
kõrge spetsiifilisusega kvantitatiivsed seroloogilised testid, kus määratakse 
antikehi vaid pertussise toksiini ehk läkaköha toksiini (PT) suhtes. Läkaköha 
seroloogilise testi kvaliteedi paranemine on väga oluline, kuna Eestis enam 
kui 90% juhtudest kinnitatakse läkaköha diagnoos ühekordse seroloogilise 
testiga. 
2) Terviseameti andmetel on läkaköha Eestis siiani diagnoositud peamiselt laste 
hulgas. Kuid ~95% 1-aastastest lastest on vaktsineeritud kolme doosi läka-
köha vaktsiiniga (165). Tõenäoliselt on haigus laste hulgas ülediagnoositud.  
3) Kuna teismelised ja täiskasvanud on läkaköha antigeenidega varem kokku 
puutunud, kas haiguse eelneva läbipõdemise teel või vaktsineerimise tõttu, 
siis neil on läkaköha kulg ja sümptomid muutunud. Enamasti põevad nad 
läkaköha kergelt või täiesti asümptoomselt ning nad ei pruugi arsti poole 
pöörduda või siis arst ei mõtle läkaköha peale ja ei uuri neid läkaköha 
suhtes.  
Läkaköha haigestumist saab uurida nii riiklikul statistikal põhinevate epidemio-
loogiliste uuringutega, prospektiivsete uuringutega köhivatel inimestel kui ka 
seroepidemioloogiliste uuringutega, kus määratakse inimeste vereseerumist PT 
IgG tüüpi antikehade kontsentratsioon ja selle põhjal hinnatakse läkaköhasse 
haigestumist. 
Läkaköhasse haigestumise kohta Eestis on varem avaldatud neli artiklit, mis 
kõik põhinevad riiklikul statistikal (6, 14-16). Kuna arstid peavad Eestis diag-
noositud läkaköha juhtudest teavitama Terviseametit, siis on riiklikul statistikal 
põhinevaid uurimistöid suhteliselt lihtne teha. Samas, ükski järelevalve süsteem 
pole ideaalne ning sel viisil kogutud andmed on suhteliselt madala tundlik-
kusega (193). Seega, et selgitada välja tegelik läkaköha avaldumus (incidence) 
ja levimus (prevalence) Eestis, viisime me läbi seroepidemioloogilise uuringu 
hindamaks B. pertussise avaldumust ja prospektiivse uuringu köhivatel patsien-
tidel. 
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Uurimistöö eesmärgid 
 
Uurimistöö peamiseks eesmärgiks oli selgitada välja B. pertussise poolt põhjus-
tatud infektsioonide epidemioloogia ja sümptomid Eestis ning hinnata, kes 
hetkel kasutusel olev immuniseerimisskeem on läkaköha suhtes optimaalne. 
Konkreetsed eesmärgid: 
1. määrata PT IgG antikehade kontsentratsiooni erinevates vanuserühmades; 
2. hinnata läkaköha infektsiooni avaldumust hiljuti mittevaktsineeritud laste ja 
täiskasvanute hulgas; 
3. võrrelda omavahel antikehadel põhinevat hinnangulist läkaköha avaldumust 
ja riiklikult registreeritud avaldumust; 
4. kindlaks määrata läkaköha ja paraläkaköha esinemine vähemalt seitse päeva 
köhinud teadmata etioloogiaga köhaga arsti vastuvõtule pöördunud patsien-
tide hulgas; 
5. kirjeldada ja omavahel võrrelda läkaköhaga, paraläkaköhaga ja muu köhaga 
patsientidel esinevaid sümptomeid ning kindlaks määrata, kui hästi MTO 
läkaköha kliiniline definitsioon ennustab haiguse olemasolu; 
6. kirjeldada läkaköha ja paraläkaköha kulgu. 
 
 
Patsiendid ja meetodid 
Laste läbilõikelisse seroepidemioloogilisse uuringusse kogusime ajavahemi-
kul 09.04.2012–23.08.2012 Tartu Ülikooli Kliinikumi Ühendlabori lastekliiniku 
osakonda saadetud alla 18-aastaste laste jääkvereseerumid koos vanuse and-
metega. 
Täiskasvanute läbilõikelisse seroepidemioloogilisse uuringusse kogusime 
ajavahemikul 07.01.2013–27.02.2013 Synlab Eesti OÜ laboritesse saadetud 18–
99-aastaste täiskasvanute jääkvereseerumid koos vanuse ja soo andmetega.  
Mõlemasse uuringusse kaasati vaid vereseerumid, mis koguti inimestelt, 
kellel ei olnud kahtlust läkaköhale. PT IgG kontsentratsiooni mõõtsime kvanti-
tatiivselt kommertsiaalse ELISA testiga (Euroimmun®, Lübeck, Saksamaa). 
Läkaköha infektsiooni levikut hindasime ainult 9–14-aastaste laste ja ≥ 20-
aastaste täiskasvanute hulgas, et vältida läkaköhavastase vaktsineerimise mõju 
antikehade kontsentratsioonile. Eeldasime, et PT IgG ≥ 62,5 IU/mL näitab 
kokkupuudet B. pertussisʼega vereanalüüsi andmisele eelneval aastal (203). 
Hinnangulise haigestumuse arvutamiseks kasutasime de Melkeri ja kaasautorite 
valemit: 365.25/208.9 × populatsiooni protsent, kellel on PT IgG ≥ 62,5 IU/mL 
(203). Üle 20-aastaste hulgas identifitseerisime inimesed, kellel PT IgG kont-
sentratsioon oli ≥ 62,5 IU/mL ja selgitasime välja, kas nad olid vereanalüüsile 
eelnenud kuue kuu jooksul kaevanud oma perearstile köha. 
Prospektiivse köhivate patsientide uuringu viisime läbi 25 perearstikesku-
ses (Harjumaal, Tartumaal, Järvamaal, Jõgevamaal ja Võrumaal) ja kolmes 
haiglas (SA Tartu Ülikooli Kliinikum, SA Tallinna Lastehaigla ja AS Järvamaa 
haigla) ajavahemikul 23.04.12–31.12.14. Uuringusse kaasasime vähemalt seitse 
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päeva kestnud ägeda köhaga lapsed ja täiskasvanud, kelle köha ei hakanud selle 
aja jooksul taanduma ja kelle köhale ei olnud teist teadaolevat põhjust. Lisaks 
pidi uuritav ja/või tema lapsevanem/hooldaja andma kirjaliku nõusoleku uurin-
gus osalemiseks.  
Esimesel visiidil registreeriti viie põhilise sümptomi (paroksüsmaalsed köha-
hood, inspiratoorsed repriisid, köhahoojärgne oksendamine, apnoed ja palavik) 
olemasolu, hinnati köha raskust Likertʼi skaalal (0 – köha ei ole, 5 – köha on 
ebamugav, segab magamist, 10 – köha on väljakannatamatu, väga valus, pidev 
hirm lämbumise ees) ja võeti patsiendilt kaks analüüsi tampooniga ninaneelust 
ja veenivere analüüs. Ühest ninaneelust kogutud proovist tehti PCR-analüüs B. 
pertussisʼele ja B. parapertussisʼele/B. bronchisepticaʼle ja teisest mikrobio-
loogiline väljakülv. Vereseerumist määrati ELISA meetodi abil kvantitatiivselt 
PT IgG kontsentratsioon ja kui see jäi vahemikku 40–100 IU/mL, siis määrati 
lisaks ka PT IgA kontsentratsioon.  
Läkaköha diagnoosi kinnitas B. pertussis isoleerimine mikrobioloogilisel 
väljakülvil ja/või B. pertussisʼe DNA tuvastamine PCR meetodil ja/või kui PT 
IgG > 100 IU/mL või kui PT IgG oli 40–100 IU/mL siis PT IgA pidi olema  
≥ 12 IU/mL. Paraläkaköha diagnoosi kinnitas B. parapertussisʼe isoleerimine 
mikrobioloogilisel väljakülvil ja/või B. parapertussisʼe DNA tuvastamine PCR 
meetodil. 
Läkaköha/paraläkaköha põdevatelt patsientidelt (või tema vanemalt) küsiti 
üks kord nädalas kuni tervistumiseni infot patsiendi haiguskulu kohta (maksi-
maalselt 12 nädala jooksul). Köha kestvust hinnati kuni köha tegeliku taandu-
miseni. 
Läkaköhaga, paraläkaköhaga ja muu köhaga patsientidel esinevate sümpto-
mite analüüsimiseks kasutasime järgimisi statistilisi meetodeid: sümptomite 
levimuse analüüs, mitmemõõtmeline korrespondentsanalüüs ja mitmene regres-
sioonianalüüs. 
 
 
Peamised tulemused 
Kokku osales uuringutes 5027 uuritavat, kellest 4478 osales seroepidemioloo-
gilises uuringus (1053 laste ning 3425 täiskasvanute uuringus) ja 549 prospek-
tiivses köhivate patsientide uuringus. 
Läbilõikelises seroepidemioloogilises uuringus oli kogu populatsiooni 
üldine PT IgG geomeetriline keskmine (GMC) madal (5,9 IU/mL; 95% usaldus-
vahemik (UV): 5,7–6,1). GMC oli numbriliselt kõrgem nendes vanusrühmades, 
kus lapsi oli hiljuti vaktsineeritud läkaköha vastu, kuid sellest juba järgmisel 
aastal langes GMC taas järsult madalale tasemele. Nooremates vanusrühmades, 
kus Eestis lapsi läkaköha vastu vaktsineeritakse (3-kuused–1-aastased ja 2-aas-
tased) tõusis GMC oluliselt kõrgemale tasemele kui vanemates vaktsineerimise 
vanusrühmades (7–8-aastased ja 18–19-aastased) – vastavalt 24,0 IU/mL (95% 
UV: 18,2–31,5) ja 11,2 IU/mL (95% UV: 9,2–13,6); p<0,001. Täiskasvanute 
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hulgas oli GMC 40–49-aastaste hulgas (3,9 IU/mL; 95% UV 3,6–4,2) oluliselt 
madalam kui teistes 10-aastastes vanusrühmades. 
Kõikidest seroepidemioloogilises uuringus osalenud uuritavatest 1,0% (95% 
UV: 0,8–1,4) olid PT IgG kontsentratsioon väga kõrges väärtuses (≥ 125 IU/mL), 
mis näitas kokkupuudet B. pertussisʼega või vaktsineerimist läkaköha vakt-
siiniga viimase 6 kuu jooksul, 3,6% (95% UV: 3.1–4.2) väärtuses 62,5– 
< 125 IU/mL, mis näitas kokkupuudet B. pertussisʼega või vaktsineerimist 
läkaköha vaktsiiniga viimase 7–12 kuu jooksul ja 39,7% (95% UV 38,3–41,2) 
5,0–< 62,5 IU/mL, mis näitas kokkupuudet B. pertussisʼega või vaktsineerimist 
läkaköha vaktsiiniga enam kui 12 kuud tagasi ning 55,6% (95% UV 54,2–57,1) 
alla 5,0 IU/mL ehk mittemääratavas tasemes, mis samas ei tähenda, et inimesel 
ei oleks kaitset läkaköha eest. Seda kinnitab ka uuringu tulemus, kus kõige 
enam mittemääratavas tasemes antikehadega uuritavaid oli 40–49-aastaste ja 
12–14-aastaste hulgas, kuid samas oli neis vanusrühmades ka väga vähe ini-
mesi, kelle antikehade tase viitaks hiljutisele läkaköha infektsioonile. Laste 
hulgas oli kõige enam kõrges või väga kõrges tasemes antikehadega uuritavaid 
vanusgruppides, kus meil Eestis lapsi läkaköha vastu vaktsineeritakse ning 
täiskasvanute hulgas 20–29-aastaste seas. Need noored täiskasvanud on olnud 
lapsed ajal kui Eestis oli läkaköhaga vaktsiiniga hõlmatus madal ning lastele 
manustati vaid üks tõhustusdoos ning võib oletada, et eelnev on tinginud suure-
ma infektsiooni leviku selles vanusgrupis. Samas, just selles vanuses saadakse 
lapsevanemateks ja need 20–29-aastased ohustavad oma veel vaktsineerimata 
või osaliselt vaktsineeritud imikuid.  
PT IgG põhinev hinnanguline läkaköha avaldumus vereanalüüsile eelnenud 
aasta jooksul oli 5,9%; 95% UV 4,9–7,0. Hinnanguline avaldumus oli kõrgem 
noorte täiskasvanute ja üle 60-aastaste inimeste hulgas. Samas, ainult 30% neist 
olid vereanalüüsile eelnenud 6 kuu jooksul kaevanud köha oma perearstile, kuid 
kedagi läkaköha suhtes ei uuritud ja seega ka mitte kellelgi läkaköha ei diag-
noositud. 
Riiklikult registreeritud läkaköha avaldumus 9–14-aastaste laste ja ≥ 20-aas-
taste täiskasvanute hulgas 2011. ja 2012. aastal oli 0,013% (12,5/100,000). See-
ga oli hinnanguline seroepidemioloogial põhinev avaldumus 470 korda kõrgem 
kui riiklikult registreeritud haiguse avaldumus. 
 
Prospektiivses köhivate patsientide uuringus diagnoositi läkaköha 22 pat-
siendil (levimus 4,0%; 95% UV: 2,5–6,0). Läkaköha levimus oli oluliselt kõr-
gem laste (< 18-aastased) 7,6%; 95% UV: 3,9–13,2 kui täiskasvanute hulgas 
2,7%; 95% UV: 1,4–4,8; p=0.027. Kõrgeim läkaköha levimus oli < 1-aastaste 
imikute hulgas 50,0, kuid üle 65-aastaste seas ühtegi läkaköha juhtu ei kinnitu-
nud. Läkaköha diagnoos kinnitus suuremal osal juhtudest (17/22) ühekordse 
seroloogilise testiga, mida võib seostada suhteliselt pika ajaperioodiga haiguse 
algusest kuni uuringusse kaasamiseni ‒ keskmiselt 26 (standardhälve (SD)± 
21.0) päeva. 
Paraläkaköha diagnoositi seitsmel patsiendil (levimus 1,3%; 95% UV: 0,5–
2,6) ja kõikidel diagnoos kinnitus PCR meetodiga. Ka paraläkaköha levimus oli 
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laste hulgas kõrgem 4,1%; 95% UV: 1,5–8,8 kui täiskasvanute hulgas 0,3%, 
95% UV: 0,0–1,4); p=0.003.  
Läkaköhaga ja paraläkaköhaga patsiendid olid keskmiselt oluliselt nooremad 
kui muu köhaga patsiendid, keskmine vanus vastavalt 21,6 (SD±17,2) aastat, 
12,0 (SD±12,5) aastat ja 35,9 (SD±21,5) aastat. Hospitaliseerimise määr oli 
läkaköhaga patsientide hulgas oluliselt kõrgem (13,7%) kui muu köhaga (1,0%) 
patsientide hulgas; suhteline risk (SR) 16,0; 95% UV: 3,1–70,6. Alla 18-aas-
taste laste hulgas oli keskmine aeg viimase läkaköha vaktsiini doosi ja läka-
köhasse haigestumise vahel 2,2 aastat (kvartiilide vahe (IQR) 1,8–7,1). Läka-
köhaga patsientidest ligi 80% olid läkaköha vastu vaktsineerimata või vaktsi-
neeritud rohkem kui viis aastat tagasi.  
Läkaköhaga patsientidel esines uuringusse haaramisel rohkem põhisümpto-
meid (2,8 ±1,1) kui muu köhaga patsientidel (2,0±1,2), p=0,001. 
Sümptomite levimuseanalüüsist selgus, et läkaköhaga patsientidel esines 
oluliselt rohkem nii köhahoojärgset oksendamist kui ka inspiratoorseid repriise 
kui muu köhaga patsientidel; SR vastavalt 9,9; 95% UV: 2,5–14,9 ja 2,9, UV: 
1,2–7,3. 
Vastavalt mitmemõõtmelisele korrespondents analüüsile ühtegi kindlat seost 
registreeritud põhisümptomite ja diagnooside vahel ei ilmnenud, kuid läkaköha-
ga täiskasvanutel esines enam inspiratoorseid repriise, köhahoojärgset oksen-
damist ja apnoesid ning lastel ka palavikku kui paraläkaköhaga ja muu köhaga 
patsientidel. Paraläkaköhaga lapsed olid sümptomite poolest sarnased ja moo-
dustasid eraldi grupi, kuid ühtegi kindlat paraläkaköhale iseloomulikku sümp-
tomit ei leitud. 
Kõigist läkaköhaga patsientidest 17 vastas ja 527-st paraläkaköhaga ja muu 
köhaga patsiendist 201 ei vastanud MTO-i läkaköha kliinilisele definitsioonile 
(109). Seega on MTO-i läkaköha kliinilise definitsiooni tundlikkus, spetsii-
filisus ja ennustustäpsus vastavalt 0,77 (95% UV: 0,55–0,92), 0.38 (95% UV: 
0,34–0,42) ja 0,58 (95% UV: 0,49–0,67) antud populatsioonis. 
Vastavalt mitmesele regressioonianalüüsile on läkaköhale iseloomulik nii 
üldpopulatsioonis kui ka täiskasvanute hulgas inspiratoorsete repriiside, köha-
hoojärgse oksendamise ja palaviku esinemine. Laste hulgas polnud ükski 
sümptomite kompleks suurema diagnostilise väärtusega kui üksiksümptomid.  
Keskmine köha kestvus nii läkaköha kui ka paraläkaköha korral oli sarnane, 
vastavalt 104.1 (±52.5) ja 78.3 (±62.9) päeva. Pärast uuringusse haaramist 
püsisid läkaköhaga patsientidel paroksüsmaalsed köhahood ja inspiratoorseid 
repriisid oluliselt kauem kui paraläkaköhaga patsientidel, vastavalt (5.0 (±3.9) 
vs 1.9 (±4.5) nädalat ja 3.7 (±4.5) vs 0.0 (±0.0) nädalat; mõlemal juhu p=0.012. 
Kõik uuringus osalenud läkaköhaga ja paraläkaköhaga patsiendid paranesid.  
 
 
Järeldused 
Alates meie uuringute algusest on Eestis riiklikult registreeritud läkaköha aval-
dumus oluliselt langenud (97/100 000 2010.a.ja 4,3/100 000 2017.a.). Riiklikult 
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registreeritud läkaköha avaldumus on püsinud stabiilselt madalana (4-5/ 
100 000) alates 2012. aastast. Nii pikka nii madala riiklikult registreeritud läka-
köha avaldumusega perioodi pole Eesti taasiseseisvumise ajal varem olnud. Ka 
riiklikult registreeritud läkaköha avaldumus imikute hulgas on madal (alla 
kolme juhu aastas viimase viie aasta jooksul). Viimane läkaköhast tingitud 
surmajuht oli 2007 aastal. Läkaköha levimus oli madal ka köhivate patsientide 
uuringus. Seega, hetkel Eestis kasutuses olev läkaköhavastane immuniseerimis-
kava on piisavalt efektiivne, et hoida läkaköha avaldumus madal tasemel. Suur 
vahe seroepidemioloogilistel uuringutel põhineva hinnangulise läkaköha aval-
dumuse ja riiklikult registreeritud avaldumuse vahel näitab, et B. pertussis ring-
leb ja, et läkaköha on enamasti asümptomaatiline või kerge kuluga haigus kõrge 
vaktsineerimistasemega riikides. Hetkel kasutuses olevate vaktsiinidega on 
võimalik vähendada läkaköha avaldumust, kuid haiguse täielik likvideerimine 
pole tõenäoliselt võimalik. 
 
Uurimistöö konkreetsed järeldused:  
1.  Eestis on PT IgG GMC madal. PT IgG GMC on kõrgeim hiljuti vaktsi-
neeritute hulgas, kuid langeb kiiresti madalale tasemele pärast vaktsineeri-
mist. Igapäevapraktikas peab meeles pidama, et seroloogiline meetod ei sobi 
läkaköha diagnoosimiseks, kui viimasest läkaköhavastasest immuniseerimi-
sest on möödas vähem kui üks aasta. 
  Enamusel seroepidemioloogilises uuringus osalejatest oli PT IgG mitte-
määrataval tasemel. Samas, väga väiksel hulgal uuritavatest olid PT IgG 
kõrgel või väga kõrgel tasemel, mis näitab hiljutist kokkupuudet B. per-
tussisʼega. Seega, vaatamata üldisele väga madalale antikehade tasemele 
uuritavate hulgas on nad suhteliselt hästi kaitstud läkaköha eest. Sellest 
järeldub, et kaitse läkaköha eest tagavad lisaks PT vastastele antikehadele 
veel muud faktorid ning populatsiooni immuunsust ei saa hinnata pelgalt 
antikehade taseme põhjal.  
2.  Seroepidemioloogial põhinev hinnanguline läkaköha avaldumus on sarnane 
kõikides täiskasvanute vanusrühmades ja hiljuti mittevaktsineeritud laste 
hulgas. Seega B. pertussis ringleb keskkonnas ja hetkel kasutuses olevate 
vaktsiinidega pole võimalik seda peatada.  
3.  Hinnanguline läkaköha avaldumus on ligi 500 korda kõrgem kui riiklikult 
registreeritud avaldumus hiljuti mittevaktsineeritud laste ja täiskasvanute 
hulgas, mis näitab asümptoomse ja/või kergekujulise B. pertussise infekt-
siooni levikut Eestis või siis pole läkaköha sümptomid teada ja seega ei tunta 
läkaköha ära.  
4.  Läkaköha levimus köhivate patsientide hulgas Eestis on madal. Kõrgeim 
levimus imikute hulgas on seotud vanusest tingitud puuduva ja/või mitte-
täieliku vaktsineerimisega selles vanusrühmas. Kuna üle 65-aastaste hulgas 
ühtegi läkaköha juhtu ei kinnitunud, siis on läkaköha selles vanusrühmas 
asümptoomne või pole köha esinemine läkaköha korral tavaline. Üldine 
madal läkaköha levimus näitab, et hetkel kasutuses olevad läkaköhavastased 
vaktsiinid ja Eestis kasutusel olev immuniseerimiskava suudavad hoida 
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sümptomaatilise läkaköha levimuse madalal tasemel. Paraläkaköha levimus 
oli veel madalam kui läkaköha levimus. 
5.  Läkaköhaga patsientidel esines enam inspiratoorseid repriise ja köhahoo-
järgset oksendamist kui muu köhaga patsientidel. Siiski on klassikaliste 
läkaköha sümptomite tundlikkus ja spetsiifilisus kõrge immuniseerimis-
tasemega riikides madal. Seega on ka hetkel kasutuses oleva MTO-i läka-
köha kliinilise definitsiooni ennustustäpsus ebapiisav. Lisaks ei sobi antud 
definitsioon läkaköha diagnoosimiseks üle 65-aastaste patsientide hulgas. 
Läkaköha paremaks diagnoosimiseks oleks vajalik välja töötada uued 
easpetsiifilised läkaköha kliinilised kriteeriumid. Paraläkaköhale iseloomu-
likke sümptomeid ei leitud. 
6.  Isegi kõrge vaktsineerimistasemega riikides võivad läkaköha ja paraläkaköha 
kulgeda pikaajalise ja piinava köhaga, kuid kõrge meditsiinilise tasemega 
riikides on surmajuhtumid harvad.  
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